<?xml version='1.0' encoding='utf-8'?>
<graphml xmlns="http://graphml.graphdrawing.org/xmlns" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://graphml.graphdrawing.org/xmlns http://graphml.graphdrawing.org/xmlns/1.0/graphml.xsd">
  <key id="d0" for="node" attr.name="label" attr.type="string" />
  <key id="d1" for="node" attr.name="type" attr.type="string" />
  <key id="d2" for="node" attr.name="community" attr.type="string" />
  <key id="d3" for="edge" attr.name="weight" attr.type="double" />
  <key id="d4" for="edge" attr.name="label" attr.type="string" />
  <key id="d5" for="node" attr.name="description" attr.type="string" />
  <key id="d6" for="edge" attr.name="full_description" attr.type="string" />
  <graph id="G" edgedefault="directed">
    <node id="0">
      <data key="d0">LEVI &amp; KORSINSKY, LLP</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">25.0</data>
      <data key="d5">Levi &amp; Korsinsky, LLP is a national securities law firm that has been actively involved in various high-profile cases and investigations related to securities fraud and other violations. The firm has a strong track record of recovering billions of dollars for investors since its formation in 2003.

Levi &amp; Korsinsky specializes in securities class action lawsuits, corporate governance, executive compensation, mergers and acquisitions, and consumer protection. The firm has served as lead counsel in some of the largest securities matters involving companies such as Tesla, US Steel, and Kraft Heinz.

The firm has also been involved in investigating and filing class action lawsuits against other companies, including Ultragenyx Pharmaceutical Inc., Vistagen Therapeutics, Inc., Alector, Inc., Capricor Therapeutics, Inc., and e.l.f. Beauty, Inc. These lawsuits are related to alleged securities fraud or other violations that have adversely affected investors.

Ed Korsinsky is a founding partner of Levi &amp; Korsinsky, LLP and is known for his expertise in securities class action litigation. The firm's focus on protecting the rights of investors and holding public companies accountable for their actions has made it a prominent player in the securities litigation landscape.

Overall, Levi &amp; Korsinsky, LLP is a well-respected law firm that has established itself as a leader in the field of securities class action litigation, with a proven track record of success in recovering significant sums of money for its clients.</data>
    </node>
    <node id="1">
      <data key="d0">OCCAM NETWORKS, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">4.0</data>
      <data key="d5">Occam Networks, Inc. was a company that was involved in a merger and acquisition litigation case. The company was acquired by Calix, Inc., and the former shareholders of Occam Networks were represented by Levi &amp; Korsinsky in litigation challenging the merger.

According to the information provided, Occam Networks, Inc. was a company that was acquired by Calix, Inc. The former shareholders of Occam Networks were represented by the law firm Levi &amp; Korsinsky in litigation challenging the merger. The litigation resulted in a preliminary injunction being obtained, and ultimately, the former shareholders of Occam Networks recovered $35 million.

The descriptions provided do not contain any contradictory information. The key details are that Occam Networks, Inc. was a company that was acquired by Calix, Inc., and the former shareholders of Occam Networks were involved in a merger and acquisition litigation case, which was successfully resolved with the help of the law firm Levi &amp; Korsinsky.

In summary, Occam Networks, Inc. was a company that was acquired by Calix, Inc., and the former shareholders of Occam Networks were involved in a merger and acquisition litigation case. The litigation was represented by the law firm Levi &amp; Korsinsky, and the former shareholders ultimately recovered $35 million as a result of the successful litigation.</data>
    </node>
    <node id="2">
      <data key="d0">CALIX, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">30.0</data>
      <data key="d5">Calix, Inc. is a company that was involved in a merger and acquisition litigation case. In 2010, Calix, Inc. acquired Occam Networks, Inc. in a merger that was challenged by the law firm Levi &amp; Korsinsky on behalf of Occam Networks' shareholders.

The details of the merger and acquisition case are as follows:

Calix, Inc. is a company that provides broadband communications access systems and software for fiber- and copper-based network architectures. In 2010, Calix, Inc. announced that it would be acquiring Occam Networks, Inc., a provider of broadband access solutions, in a merger transaction.

However, the merger was challenged by the law firm Levi &amp; Korsinsky, which filed a class action lawsuit on behalf of the shareholders of Occam Networks. The lawsuit alleged that the terms of the merger were unfair and did not adequately compensate Occam Networks' shareholders for the value of their shares.

The lawsuit claimed that the merger price of $7.75 per share was too low and did not reflect the true value of Occam Networks. The lawsuit also alleged that the Occam Networks' board of directors had breached their fiduciary duties to the shareholders by approving the merger on unfavorable terms.

The outcome of the litigation case is not clear from the information provided. However, the fact that Calix, Inc. was involved in a merger and acquisition litigation case suggests that there were some legal and financial complexities surrounding the acquisition of Occam Networks.

In summary, Calix, Inc. is a company that was involved in a merger and acquisition litigation case related to its acquisition of Occam Networks, Inc. in 2010. The lawsuit was filed by the law firm Levi &amp; Korsinsky on behalf of Occam Networks' shareholders, who alleged that the merger terms were unfair and did not adequately compensate them for the value of their shares.</data>
    </node>
    <node id="3">
      <data key="d0">HEALTH GRADES, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">23.0</data>
      <data key="d5">Health Grades, Inc. is a company that was involved in a merger and acquisition litigation case. According to the information provided, Health Grades, Inc. was acquired by affiliates of Vestar Capital Partners, L.P.

The descriptions indicate that Levi &amp; Korsinsky, a law firm, represented Health Grades' shareholders in this case. The law firm successfully demonstrated that the defendants, likely referring to the acquirer or other parties involved in the acquisition, had likely breached their fiduciary duties by failing to maximize value for the shareholders. This led to a favorable settlement for the Health Grades shareholders.

The summary of the data provided is that Health Grades, Inc. was involved in a merger and acquisition litigation case, where the company was acquired by Vestar Capital Partners, L.P. The shareholders of Health Grades were represented by Levi &amp; Korsinsky, who were able to show that the defendants had breached their fiduciary duties, resulting in a favorable settlement for the shareholders.</data>
    </node>
    <node id="4">
      <data key="d0">VESTAR CAPITAL PARTNERS, L.P.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">30.0</data>
      <data key="d5">Vestar Capital Partners, L.P. is a private equity firm that was involved in the acquisition of Health Grades, Inc. The firm acquired Health Grades, Inc., a healthcare quality ratings and information company, in a transaction that was challenged by the law firm Levi &amp; Korsinsky on behalf of Health Grades' shareholders.

Vestar Capital Partners, L.P. is a private equity firm that focuses on investing in and acquiring companies across various industries, including healthcare, consumer, and business services. The firm has a long history of successful investments and has been involved in numerous transactions over the years.

The acquisition of Health Grades, Inc. by Vestar Capital Partners, L.P. was a significant event for both companies. Health Grades, Inc. is a leading provider of healthcare quality ratings and information, and the acquisition was seen as a strategic move to expand Vestar's presence in the healthcare sector.

However, the transaction was not without controversy. The law firm Levi &amp; Korsinsky challenged the acquisition on behalf of Health Grades' shareholders, alleging that the terms of the deal were not fair and that the shareholders were not receiving adequate compensation.

Despite the legal challenge, Vestar Capital Partners, L.P. was able to successfully complete the acquisition of Health Grades, Inc. The firm's experience and expertise in the healthcare industry likely played a key role in the successful completion of the transaction.

Overall, Vestar Capital Partners, L.P.'s involvement in the acquisition of Health Grades, Inc. demonstrates the firm's continued focus on expanding its portfolio and investing in companies that it believes have strong growth potential. The firm's ability to navigate the legal challenges and complete the transaction is a testament to its expertise and strategic vision.</data>
    </node>
    <node id="5">
      <data key="d0">CNX GAS CORP.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">25.0</data>
      <data key="d5">CNX Gas Corp. is a company that was involved in a shareholder litigation case. Levi &amp; Korsinsky, a prominent law firm, played a significant role in the matter of In re CNX Gas Corp. Shareholders Litigation. As a result of this litigation, plaintiffs were able to recover a common fund of over $42.7 million for the company's stockholders.

The shareholder litigation case against CNX Gas Corp. appears to have been a successful endeavor, with the plaintiffs recovering a substantial amount of money on behalf of the company's shareholders. Levi &amp; Korsinsky, a well-known law firm specializing in shareholder rights and corporate governance, was instrumental in this matter, helping to secure the $42.7 million common fund for the affected stockholders.

While the details of the specific allegations and the nature of the dispute are not provided in the given information, the outcome of the litigation suggests that the plaintiffs were able to address and resolve issues related to the company's governance or actions that were deemed detrimental to the interests of its shareholders. The successful recovery of the common fund indicates that the plaintiffs were able to demonstrate the merits of their case and obtain a favorable resolution for the affected stockholders.

Overall, the summary highlights the involvement of CNX Gas Corp. in a shareholder litigation case, the prominent role played by Levi &amp; Korsinsky in the matter, and the successful recovery of a substantial common fund for the company's stockholders as a result of the litigation.</data>
    </node>
    <node id="6">
      <data key="d0">JOSEPH E. LEVI</data>
      <data key="d1" />
      <data key="d2">30.0</data>
      <data key="d5" />
    </node>
    <node id="7">
      <data key="d0">CHEN V. HOWARD-ANDERSON</data>
      <data key="d1">EVENT</data>
      <data key="d2">25.0</data>
      <data key="d5">The case Chen v. Howard-Anderson, No. 5878-VCL (Del. Ch. Jan. 24, 2011), in which Levi &amp; Korsinsky obtained a preliminary injunction against the merger of Occam Networks and Calix due to material misrepresentations and omissions in the proxy statement.</data>
    </node>
    <node id="8">
      <data key="d0">WEIGARD V. HICKS</data>
      <data key="d1">EVENT</data>
      <data key="d2">25.0</data>
      <data key="d5">The case Weigard v. Hicks, No. 5732-VCS (Del. Ch. Sept. 3, 2010), in which Levi &amp; Korsinsky successfully demonstrated to the Delaware Court of Chancery that the defendants had likely breached their fiduciary duties to Health Grades' shareholders by failing to maximize value.</data>
    </node>
    <node id="9">
      <data key="d0">IN RE CNX GAS CORP. SHAREHOLDERS LITIGATION</data>
      <data key="d1">EVENT</data>
      <data key="d2">25.0</data>
      <data key="d5">The matter of In re CNX Gas Corp. Shareholders Litigation, C.A. No. 5377-VCL (Del. Ch. 2010), in which Levi &amp; Korsinsky played a prominent role and plaintiffs recovered a common fund of over $42.7 million for stockholders.</data>
    </node>
    <node id="10">
      <data key="d0">CAPRICOR THERAPEUTICS, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">14.0</data>
      <data key="d5">Capricor Therapeutics, Inc. is a biopharmaceutical company that is developing a lead cell therapy candidate drug called deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The company is focused on the discovery, development, and commercialization of novel therapies for the treatment of cardiovascular and other diseases.

Capricor Therapeutics, Inc. is a public company that was sued in a securities fraud class action lawsuit by Levi &amp; Korsinsky. The lawsuit alleged that the company made false and misleading statements about the development and prospects of its lead product candidate, deramiocel. Specifically, the lawsuit claimed that Capricor Therapeutics failed to disclose that the clinical trial for deramiocel was not progressing as well as the company had represented, and that the company's financial projections were overly optimistic.

Despite the legal challenges, Capricor Therapeutics remains committed to the development of deramiocel and other potential therapies for the treatment of cardiovascular and other diseases. The company's lead product candidate, deramiocel, is a cell therapy that is being developed for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). DMD is a rare and devastating genetic disorder that primarily affects young boys, causing progressive muscle weakness and ultimately leading to heart and respiratory failure.

Capricor Therapeutics is currently conducting clinical trials to evaluate the safety and efficacy of deramiocel in patients with DMD-associated cardiomyopathy. The company has reported promising results from its early-stage trials, which have shown that deramiocel has the potential to improve cardiac function and reduce the risk of heart failure in these patients.

Despite the ongoing legal proceedings, Capricor Therapeutics remains focused on advancing its pipeline of innovative therapies and addressing the significant unmet medical needs of patients with cardiovascular and other diseases. The company is committed to working closely with regulatory authorities, healthcare providers, and patient advocacy groups to bring its therapies to market and improve the lives of those affected by these devastating conditions.</data>
    </node>
    <node id="11">
      <data key="d0">U.S. FOOD AND DRUG ADMINISTRATION (FDA)</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">14.0</data>
      <data key="d5">The U.S. Food and Drug Administration (FDA) is the federal agency responsible for regulating and supervising the safety of food, drugs, and other products in the United States. As the regulatory agency that reviews and approves new drugs and biologics, the FDA plays a crucial role in ensuring the safety and efficacy of pharmaceutical products before they can be made available to the public.

In the case of Capricor's Biologics License Application (BLA) for deramiocel, the FDA has denied the application, citing a lack of substantial evidence of effectiveness and the need for additional clinical data. This decision highlights the FDA's rigorous standards and its commitment to protecting the health and well-being of American consumers.

The FDA's role in the drug approval process is to thoroughly evaluate the safety and efficacy of new pharmaceutical products through a comprehensive review of clinical trial data and other relevant information. This process is designed to ensure that only safe and effective drugs are made available to the public, and the FDA's decision to deny Capricor's BLA for deramiocel is a reflection of this commitment.

While the FDA's decision may be disappointing for Capricor and the patients who were hoping for access to deramiocel, it is important to recognize the agency's responsibility to uphold the highest standards of safety and efficacy. The FDA's actions in this case demonstrate its dedication to protecting the public and its willingness to make difficult decisions when necessary.

Overall, the U.S. Food and Drug Administration plays a vital role in the regulation and supervision of the pharmaceutical industry, ensuring that American consumers have access to safe and effective drugs and biologics. The agency's decision regarding Capricor's BLA for deramiocel is a testament to its commitment to this important mission.</data>
    </node>
    <node id="12">
      <data key="d0">LEVI &amp; KORSINSKY</data>
      <data key="d1" />
      <data key="d2">11.0</data>
      <data key="d5" />
    </node>
    <node id="13">
      <data key="d0">DERAMIOCEL</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">15.0</data>
      <data key="d5">Deramiocel is Capricor Therapeutics' lead cell therapy candidate drug for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Cardiomyopathy is a common complication of DMD, a rare and fatal genetic disorder that causes progressive muscle degeneration and weakness.

Deramiocel is a type of cell therapy that uses allogeneic (derived from a different person) cardiosphere-derived cells (CDCs) to target the cardiac complications of DMD. CDCs are a specific type of stem cell that can differentiate into various cardiac cell types, including cardiomyocytes, endothelial cells, and smooth muscle cells. The goal of Deramiocel is to regenerate and repair damaged cardiac tissue in DMD patients, potentially improving heart function and overall quality of life.

Capricor Therapeutics, a clinical-stage biotechnology company, is currently developing Deramiocel as a potential treatment for DMD-associated cardiomyopathy. The company has conducted several clinical trials to evaluate the safety and efficacy of Deramiocel in this patient population. The results of these trials have been promising, suggesting that Deramiocel may have the potential to improve cardiac function and slow the progression of cardiomyopathy in DMD patients.

Overall, Deramiocel represents a novel and innovative approach to addressing the cardiac complications of Duchenne muscular dystrophy, a devastating disease that currently has limited treatment options. As Capricor Therapeutics continues to advance the development of Deramiocel, it holds the promise of providing a much-needed therapeutic option for DMD patients and their families.</data>
    </node>
    <node id="14">
      <data key="d0">DUCHENNE MUSCULAR DYSTROPHY (DMD)</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">15.0</data>
      <data key="d5">Duchenne Muscular Dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. It is a severe and debilitating condition that primarily affects young boys.

DMD is caused by a mutation in the dystrophin gene, which is responsible for producing a protein essential for maintaining the structural integrity of muscle fibers. Without this protein, the muscle fibers gradually break down, leading to a progressive loss of muscle function and strength.

The symptoms of DMD typically begin to manifest in early childhood, with affected individuals experiencing difficulty in performing physical activities, such as walking and climbing stairs. As the disease progresses, the muscles in the limbs, trunk, and respiratory system become increasingly weaker, leading to the need for assistive devices, such as wheelchairs, and eventually, the need for mechanical ventilation.

In addition to the muscle weakness, individuals with DMD may also experience cardiomyopathy, a condition in which the heart muscle becomes weakened and unable to pump blood effectively. This can lead to heart failure and other cardiovascular complications.

Capricor Therapeutics, a biopharmaceutical company, is currently developing a treatment called deramiocel for the cardiomyopathy associated with DMD. Deramiocel is a cell-based therapy that aims to improve the function of the heart muscle and potentially slow the progression of the disease.

While there is currently no cure for DMD, ongoing research and clinical trials are exploring various treatment approaches, including gene therapy, stem cell therapy, and pharmacological interventions, with the goal of improving the quality of life and extending the lifespan of individuals affected by this devastating condition.

In summary, Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration and weakness, as well as associated cardiomyopathy. Capricor Therapeutics is developing a cell-based therapy, deramiocel, to address the cardiomyopathy aspect of the disease, and ongoing research is focused on finding more effective treatments to manage and potentially slow the progression of this debilitating condition.</data>
    </node>
    <node id="15">
      <data key="d0">ED KORSINSKY</data>
      <data key="d1">PERSON</data>
      <data key="d2">12.0</data>
      <data key="d5">Ed Korsinsky is an attorney at Levi &amp; Korsinsky, LLP, a law firm that specializes in complex securities litigation. Korsinsky has been involved in several high-profile cases, representing shareholders and investors in various companies.

Korsinsky is currently representing Vistagen Therapeutics shareholders in a lawsuit against the company. He is also handling a class action lawsuit against e.l.f. Beauty, Inc. Additionally, Korsinsky is involved in the Capricor Therapeutics securities fraud lawsuit, representing investors in that case.

Korsinsky's background suggests that he has a strong interest in both law and technology. He grew up in a technologically-inclined household and has leveraged his expertise in these areas to provide unique value-adds to his clients in complex securities litigation cases. As the managing partner of Levi &amp; Korsinsky, Korsinsky has built the firm with the goal of using technology to enhance the firm's capabilities in handling these types of cases.

Overall, Ed Korsinsky is an experienced and accomplished attorney who has taken on high-profile cases involving various companies and their shareholders or investors. His background in both law and technology has allowed him to bring a unique perspective and approach to his work, which has likely contributed to his success in representing his clients in complex securities litigation matters.</data>
    </node>
    <node id="16">
      <data key="d0">LEVI &amp; KORSINSKY LLP</data>
      <data key="d1" />
      <data key="d2">31.0</data>
      <data key="d5" />
    </node>
    <node id="17">
      <data key="d0">ISS SECURITIES CLASS ACTION SERVICES</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">31.0</data>
      <data key="d5">ISS Securities Class Action Services is a service that ranks securities litigation firms, and has ranked Levi &amp; Korsinsky LLP as one of the top securities litigation firms in the United States for seven years in a row.</data>
    </node>
    <node id="18">
      <data key="d0">ACCESS NEWSWIRE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">31.0</data>
      <data key="d5">ACCESS Newswire is a platform that Levi &amp; Korsinsky LLP used to publish a press release.</data>
    </node>
    <node id="19">
      <data key="d0">CORE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">11.0</data>
      <data key="d5">CORE is a technological service developed by the attorneys at Levi &amp; Korsinsky, a law firm. CORE is a platform that allows for seamless input of court developments and provides real-time updates to the firm's clients.

The primary purpose of CORE is to enable clients to track the firm's work on their cases in real-time and recover damages. The platform was developed by Levi &amp; Korsinsky to facilitate efficient communication and collaboration between the firm and its clients.

CORE provides a centralized hub where clients can access information about the progress of their cases, including court filings, hearing schedules, and settlement negotiations. The platform allows for the real-time input of court developments, ensuring that clients are always informed about the status of their cases.

One of the key features of CORE is its ability to help clients recover damages. The platform provides tools and resources that assist the firm's attorneys in building strong cases and negotiating favorable settlements on behalf of their clients. By leveraging the data and insights available through CORE, Levi &amp; Korsinsky can more effectively advocate for their clients' interests and secure the best possible outcomes.

Overall, CORE is a valuable tool that enhances the client experience and streamlines the legal process. By offering real-time updates and facilitating effective communication, the platform helps to build trust and strengthen the relationship between Levi &amp; Korsinsky and its clients.</data>
    </node>
    <node id="20">
      <data key="d0">E-TRADE FINANCIAL CORP.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">11.0</data>
      <data key="d5">E-Trade Financial Corp. was involved in a securities litigation case where Levi &amp; Korsinsky recovered $79 million for the firm's clients.</data>
    </node>
    <node id="21">
      <data key="d0">GOOGLE INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">11.0</data>
      <data key="d5">Google Inc. is a technology company that was recently involved in a shareholder litigation case. The case was related to the company's Class C stock, which was the subject of a corporate governance matter.

According to the provided descriptions, Google Inc. was embroiled in a shareholder litigation case. The case appears to have been centered around the company's Class C stock, which was the focus of a corporate governance issue. 

The law firm Levi &amp; Korsinsky played a role in this matter, as they indemnified Google Inc. investors for up to $522 million in losses related to the corporate governance issue. This suggests that the shareholders may have suffered significant financial losses due to the company's actions or decisions regarding the Class C stock.

The details of the shareholder litigation case and the specific corporate governance matter are not fully clear from the provided information. However, the descriptions indicate that there were some issues or controversies surrounding Google Inc.'s handling of its Class C stock, which led to a legal dispute with its shareholders.

Overall, Google Inc. found itself in a challenging situation due to a shareholder litigation case related to its Class C stock. The company was required to indemnify its investors for substantial losses, suggesting that the corporate governance matter had a significant financial impact on the shareholders. While the full context and details of the case are not provided, it is clear that Google Inc. faced a complex legal and financial issue that required resolution.</data>
    </node>
    <node id="22">
      <data key="d0">TECHNOLOGY</data>
      <data key="d1" />
      <data key="d2">12.0</data>
      <data key="d5" />
    </node>
    <node id="23">
      <data key="d0">IBM PC</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">The IBM PC was one of the first personal computers that Ed Korsinsky's father acquired and used for various technology projects.</data>
    </node>
    <node id="24">
      <data key="d0">FACIAL RECOGNITION</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">Ed Korsinsky's father worked on developing facial recognition software and hardware, which Korsinsky helped with as a child.</data>
    </node>
    <node id="25">
      <data key="d0">NICK PORRITT</data>
      <data key="d1">PERSON</data>
      <data key="d2">11.0</data>
      <data key="d5">Nick Porritt is a partner at Levi &amp; Korsinsky based in Washington D.C. who began his legal career in New Zealand</data>
    </node>
    <node id="26">
      <data key="d0">GREG NESPOLE</data>
      <data key="d1">PERSON</data>
      <data key="d2">11.0</data>
      <data key="d5">Greg Nespole is a partner at Levi &amp; Korsinsky who previously defended suspects in organized crime and racketeering cases before moving into securities litigation</data>
    </node>
    <node id="27">
      <data key="d0">AMERISOURCEBERGEN</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">11.0</data>
      <data key="d5">AmerisourceBergen is a pharmaceutical company that Levi &amp; Korsinsky is representing shareholders in lawsuits against over the opioid crisis</data>
    </node>
    <node id="28">
      <data key="d0">WALMART</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">11.0</data>
      <data key="d5">Walmart is a company that Levi &amp; Korsinsky is representing shareholders in lawsuits against over the opioid crisis, as Walmart pharmacies filled prescriptions for opioid painkillers</data>
    </node>
    <node id="29">
      <data key="d0">KORSINSKY</data>
      <data key="d1">PERSON</data>
      <data key="d2">11.0</data>
      <data key="d5">Korsinsky is a co-founder of Levi &amp; Korsinsky who discussed the firm's approach to building a better workplace for its employees</data>
    </node>
    <node id="30">
      <data key="d0">EMPLOYEE CULTURE</data>
      <data key="d1" />
      <data key="d2">11.0</data>
      <data key="d5" />
    </node>
    <node id="31">
      <data key="d0">EDUARD KORSINSKY</data>
      <data key="d1">PERSON</data>
      <data key="d2">2.0</data>
      <data key="d5">Eduard Korsinsky is the Managing Partner and Co-Founder of Levi &amp; Korsinsky LLP, a national securities firm. He has over 24 years of experience representing investors and institutional shareholders in complex securities matters.

Korsinsky has achieved significant recoveries for stockholders through his work at Levi &amp; Korsinsky LLP. The firm has recovered billions of dollars for investors over the years. Korsinsky's expertise lies in representing investors and institutional shareholders in complex securities cases, where he has demonstrated a track record of success.

As the Managing Partner and Co-Founder of Levi &amp; Korsinsky LLP, Korsinsky has played a crucial role in the firm's growth and success. He has leveraged his extensive experience and legal acumen to secure favorable outcomes for his clients, whether they are individual investors or large institutional shareholders.

Korsinsky's commitment to protecting the rights of investors is evident in his work. He has dedicated his career to ensuring that investors are treated fairly and that their interests are safeguarded, even in the face of complex financial and legal challenges.

Through his leadership and expertise, Korsinsky has established Levi &amp; Korsinsky LLP as a respected and trusted name in the securities litigation field. The firm's success in recovering billions of dollars for its clients is a testament to Korsinsky's dedication and his ability to navigate the intricate landscape of securities law.

In summary, Eduard Korsinsky is a seasoned legal professional with over 24 years of experience in representing investors and institutional shareholders in complex securities matters. As the Managing Partner and Co-Founder of Levi &amp; Korsinsky LLP, he has played a pivotal role in the firm's success, securing significant recoveries for its clients and establishing the firm as a leader in the securities litigation field.</data>
    </node>
    <node id="32">
      <data key="d0">E-TRADE FINANCIAL CORPORATION</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">2.0</data>
      <data key="d5">E-TRADE FINANCIAL CORPORATION

E-Trade Financial Corporation is a company that has been involved in a securities case, where investors were able to recover $79 million. The law firm Levi &amp; Korsinsky LLP was responsible for achieving this $79 million recovery for the investors of E-Trade Financial Corporation.

The descriptions provided indicate that E-Trade Financial Corporation was the subject of a securities case, where investors were able to recover a significant amount of money. While the descriptions mention different individuals and firms involved in the case, they all converge on the key details that Levi &amp; Korsinsky LLP recovered $79 million for investors of E-Trade Financial Corporation.

There are no apparent contradictions in the information provided, and the descriptions can be seamlessly combined into a comprehensive summary. The entity name, E-TRADE FINANCIAL CORPORATION, is clearly identified, and the details about the securities case and the recovery of $79 million for investors are consistently reported across the descriptions.

In summary, E-TRADE FINANCIAL CORPORATION is a company that was involved in a securities case, where investors were able to recover $79 million through the efforts of the law firm Levi &amp; Korsinsky LLP.</data>
    </node>
    <node id="33">
      <data key="d0">GOOGLE, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">2.0</data>
      <data key="d5">Google, Inc. is a prominent technology company that was involved in a significant corporate governance case. According to the information provided, the law firm of Levi &amp; Korsinsky LLP achieved a payment ladder that indemnified investors of Google, Inc. up to $8 billion in losses on a ground-breaking corporate governance case.

The details of the case are not fully clear from the provided descriptions, but it appears that the case was related to corporate governance issues at Google, Inc. and resulted in a substantial financial settlement or indemnification for affected investors. The case seems to have been a significant and impactful one, described as "ground-breaking" in the context of corporate governance.

While the exact nature of the case and the specific issues involved are not specified, the outcome highlights the importance of strong corporate governance practices and the potential consequences for companies that fail to uphold them. The fact that investors were able to recover up to $8 billion in losses suggests the magnitude of the case and its impact on Google, Inc. and its stakeholders.

Overall, this summary provides a high-level overview of the key information related to Google, Inc.'s involvement in a notable corporate governance case, where a law firm was able to secure a substantial financial settlement or indemnification for affected investors. The case appears to have been a significant event in the company's history and underscores the importance of effective corporate governance practices in the technology industry.</data>
    </node>
    <node id="34">
      <data key="d0">TESLA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">25.0</data>
      <data key="d5">Tesla is an American electric vehicle and clean energy company that designs and manufactures electric cars, energy storage products, and related products. The company has been involved in several significant securities matters, with Levi &amp; Korsinsky LLP serving as lead counsel.

According to the provided descriptions, Levi &amp; Korsinsky LLP serves as lead counsel in a securities matter involving Tesla. This appears to be one of the largest securities matters that the law firm is handling, as it is described as "one of the largest securities matters" that Levi &amp; Korsinsky LLP serves as lead counsel.

The descriptions also indicate that Levi &amp; Korsinsky LLP serves as lead counsel in some of the largest securities matters involving Tesla. This suggests that the company has been involved in multiple significant securities-related legal proceedings, with the law firm playing a prominent role in representing Tesla's interests.

Overall, the provided information paints a picture of Tesla as a prominent and influential company in the electric vehicle and clean energy industries, with a significant legal presence and involvement in high-profile securities matters. The company's size and significance in the market is reflected in the scale and importance of the securities cases that Levi &amp; Korsinsky LLP is handling on its behalf.</data>
    </node>
    <node id="35">
      <data key="d0">US STEEL</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">25.0</data>
      <data key="d5">US Steel is a major steel company that has been involved in several significant securities matters, with Levi &amp; Korsinsky LLP serving as the lead counsel. According to the provided descriptions, Levi &amp; Korsinsky LLP is involved in some of the largest securities matters related to US Steel, indicating that the company has faced substantial legal challenges in the financial realm.

The descriptions suggest that US Steel is one of the largest securities matters that Levi &amp; Korsinsky LLP has handled as the lead counsel. This implies that the legal issues surrounding US Steel are substantial and complex, requiring the expertise and resources of a prominent law firm like Levi &amp; Korsinsky LLP.

While the descriptions do not provide specific details about the nature of the securities matters involving US Steel, the fact that Levi &amp; Korsinsky LLP is serving as the lead counsel suggests that the issues are significant and have the potential to impact the company's financial standing and operations.

Overall, the summary indicates that US Steel is a major player in the steel industry, but has also faced significant legal challenges related to securities matters. The involvement of Levi &amp; Korsinsky LLP as the lead counsel in these matters underscores the importance and complexity of the issues at hand.</data>
    </node>
    <node id="36">
      <data key="d0">KRAFT HEINZ</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">25.0</data>
      <data key="d5">Kraft Heinz is a major food and beverage company that has been involved in several significant securities matters. Levi &amp; Korsinsky LLP, a law firm, serves as the lead counsel in these securities cases involving Kraft Heinz.

According to the information provided, Levi &amp; Korsinsky LLP is responsible for handling some of the largest securities matters related to Kraft Heinz. The law firm is serving as the lead counsel in these cases, which suggests that they are playing a central role in representing the interests of investors or other parties involved in the securities issues.

The descriptions indicate that the securities matters involving Kraft Heinz are substantial in nature, as the law firm is handling "one of the largest securities matters" and "some of the largest securities matters" related to the company. This implies that Kraft Heinz has faced significant legal challenges or disputes in the securities realm, which have required the expertise and leadership of Levi &amp; Korsinsky LLP to navigate.

While the specific details of the securities cases are not provided, the consistent references to Levi &amp; Korsinsky LLP's role as the lead counsel suggest that these matters are of considerable importance and complexity. The law firm's involvement as the lead counsel indicates that they have been entrusted with the primary responsibility for representing the interests of the parties involved, whether they are investors, regulators, or the company itself.

In summary, Kraft Heinz, a major food and beverage company, has been involved in several significant securities matters, and Levi &amp; Korsinsky LLP serves as the lead counsel in these cases. The law firm's central role in handling these large-scale securities issues underscores the importance and complexity of the legal challenges faced by Kraft Heinz in this domain.</data>
    </node>
    <node id="37">
      <data key="d0">CORE MONITORING SYSTEMS LLC</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">2.0</data>
      <data key="d5">CORE Monitoring Systems LLC is a technology platform co-founded by Eduard Korsinsky to assist institutional clients more effectively monitor their investment portfolios and maximize recoveries on securities litigation. The company was founded with the goal of providing a comprehensive solution for institutional investors to better track and manage their investments.

CORE Monitoring Systems LLC utilizes advanced data analytics and monitoring tools to help clients stay informed about the performance of their investment portfolios. The platform provides real-time insights and alerts, allowing clients to quickly identify and address any issues or opportunities that arise. This helps institutions make more informed decisions and optimize their investment strategies.

In addition to portfolio monitoring, CORE Monitoring Systems LLC also specializes in assisting clients with securities litigation. The company's team of experts helps clients navigate the complex legal landscape, identify potential claims, and maximize the recovery of any settlements or judgments. This service is particularly valuable for institutional investors who may have exposure to a wide range of securities and need support in managing their litigation efforts.

Overall, CORE Monitoring Systems LLC is a valuable resource for institutional clients looking to enhance their investment management and securities litigation capabilities. The company's innovative technology and experienced team provide a comprehensive solution that helps clients achieve their financial goals and protect their interests. By offering a seamless integration of portfolio monitoring and litigation support, CORE Monitoring Systems LLC has established itself as a leader in the investment management technology space.</data>
    </node>
    <node id="38">
      <data key="d0">NEW YORK UNIVERSITY SCHOOL OF LAW</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">2.0</data>
      <data key="d5">New York University School of Law

New York University School of Law is a prestigious law school located in New York City. It is one of the top-ranked law schools in the United States and is known for its excellence in legal education and research.

According to the provided descriptions, Eduard Korsinsky received his LL.M. (Master of Laws) degree from the New York University School of Law. The descriptions indicate that Korsinsky's LL.M. was specifically in the field of Taxation, which suggests that the school offers a strong program in tax law.

The descriptions provide consistent information about Korsinsky's degree, stating that he received an LL.M. from the New York University School of Law in 1997. The descriptions use slightly different wording, such as "Master of Law(s) Taxation" and "LL.M. in Taxation," but these variations are minor and do not contradict the core information that Korsinsky obtained an LL.M. degree from the school.

Overall, the provided descriptions paint a positive picture of the New York University School of Law as a leading institution for legal education, particularly in the field of taxation. The school's reputation and the successful completion of an LL.M. degree by Eduard Korsinsky suggest that the New York University School of Law offers a high-quality and rigorous educational experience for its students.</data>
    </node>
    <node id="39">
      <data key="d0">BROOKLYN LAW SCHOOL</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">2.0</data>
      <data key="d5">Brooklyn Law School is a private law school located in Brooklyn, New York. It was founded in 1901 and is one of the oldest law schools in the United States.

According to the provided descriptions, Eduard Korsinsky received his Juris Doctor (J.D.) degree from Brooklyn Law School. The descriptions indicate that he graduated from the law school in 1995, though the exact date is not specified in all of the descriptions.

The descriptions do not provide any additional details about Brooklyn Law School or Eduard Korsinsky's experience there. However, the consistent information across the descriptions suggests that Eduard Korsinsky successfully completed his legal education at Brooklyn Law School and obtained his J.D. degree from the institution.

In summary, Brooklyn Law School is a well-established private law school, and Eduard Korsinsky is an alumnus who graduated with a J.D. degree from the school in 1995.</data>
    </node>
    <node id="40">
      <data key="d0">BROOKLYN COLLEGE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">2.0</data>
      <data key="d5">Brooklyn College is a public college located in Brooklyn, New York. According to the provided descriptions, Eduard Korsinsky received a Bachelor of Science (B.S.) degree in Accounting from Brooklyn College in 1992. He graduated summa cum laude, which is the highest academic distinction awarded to students who have achieved a near-perfect grade point average.

The descriptions consistently state that Korsinsky received his B.S. in Accounting from Brooklyn College, and that he graduated summa cum laude. The only minor difference is the exact wording used to describe his degree and graduation, but the core information is the same across all three descriptions.

In summary, Eduard Korsinsky is an alumnus of Brooklyn College, having earned a B.S. degree in Accounting in 1992, graduating with the highest academic honors, summa cum laude.</data>
    </node>
    <node id="41">
      <data key="d0">PAMRAPO BANCORP</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">30.0</data>
      <data key="d5">Pamrapo Bancorp is a company that was involved in shareholder litigation</data>
    </node>
    <node id="42">
      <data key="d0">M.D.C. HOLDINGS, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">30.0</data>
      <data key="d5">M.D.C. HOLDINGS, INC.

M.D.C. Holdings, Inc. is a company that was involved in a shareholder litigation case. The case was related to "say on pay" voting, which refers to the ability of shareholders to vote on the compensation of a company's executives.

According to the provided descriptions, M.D.C. Holdings, Inc. was the subject of a shareholder litigation case. The case appears to have been focused on the company's "say on pay" voting practices, which allow shareholders to have a say in the compensation of the company's executives.

"Say on pay" voting is a mechanism that has been implemented in many countries to give shareholders a voice in the executive compensation decisions of publicly traded companies. The goal is to increase transparency and accountability in the process of setting executive pay.

The details of the specific case involving M.D.C. Holdings, Inc. are not provided in the given information. However, it is clear that the company was embroiled in a shareholder litigation matter related to its "say on pay" voting practices.

Shareholder litigation cases can arise for a variety of reasons, such as allegations of mismanagement, financial impropriety, or violations of shareholder rights. In the case of "say on pay" voting, shareholders may challenge the company's executive compensation policies or the way in which the voting process is conducted.

Overall, the provided information indicates that M.D.C. Holdings, Inc. was involved in a shareholder litigation case related to its "say on pay" voting practices. The case appears to have been a matter of concern for the company and its shareholders, though the specific details and outcomes are not known based on the given data.</data>
    </node>
    <node id="43">
      <data key="d0">I2 TECHNOLOGIES, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">30.0</data>
      <data key="d5">I2 TECHNOLOGIES, INC.

I2 Technologies, Inc. is a company that was involved in a shareholder litigation case. The case challenged the fairness of certain asset sales made by the company.

The shareholder litigation case was brought against I2 Technologies, Inc. by its shareholders. The shareholders alleged that the company's asset sales were not fair to the shareholders and did not maximize the value of the company's assets.

The details of the asset sales that were challenged in the litigation are not fully clear from the information provided. However, it seems that the shareholders believed the company could have obtained a better deal or higher value for the assets it sold.

The shareholder litigation case was likely an attempt by the shareholders to hold the company's management accountable and ensure that their interests were properly represented in major corporate decisions, such as asset sales.

Ultimately, the outcome of the shareholder litigation case is not specified. It is unclear whether the shareholders were successful in their challenge or if the company's actions were ultimately deemed fair and appropriate.

In summary, I2 Technologies, Inc. was involved in a shareholder litigation case that challenged the fairness of certain asset sales made by the company. The shareholders believed the sales did not maximize value for them, but the final resolution of the case is unknown based on the information provided.</data>
    </node>
    <node id="44">
      <data key="d0">BEAZER HOMES</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">30.0</data>
      <data key="d5">Beazer Homes is a company that has been involved in a shareholder litigation case. The company was the subject of a lawsuit regarding its executive compensation practices.

According to the information provided, Beazer Homes is a company that has been embroiled in a shareholder litigation case. The details of the case indicate that it was related to the company's executive compensation policies and practices.

The descriptions suggest that Beazer Homes faced a lawsuit from its shareholders regarding the way it compensated its top executives. While the exact nature of the case is not specified, it appears that the shareholders were dissatisfied with the compensation arrangements and sought legal action against the company.

The descriptions do not provide any further details about the outcome of the litigation or the specific allegations made by the shareholders. However, the fact that Beazer Homes was involved in such a case suggests that there were concerns or controversies surrounding the company's executive compensation practices.

Overall, the summary indicates that Beazer Homes, a company involved in the home building industry, has faced a shareholder lawsuit related to its executive compensation policies. The case appears to have been a source of controversy and legal action for the company, though the ultimate resolution or impact of the litigation is not clear from the information provided.</data>
    </node>
    <node id="45">
      <data key="d0">NCS HEALTHCARE, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">30.0</data>
      <data key="d5">NCS Healthcare, Inc. is a company that has been involved in legal proceedings related to shareholder and securities litigation. 

According to the information provided, NCS Healthcare, Inc. was involved in a shareholder litigation case. The details of this case are not fully clear, but it appears to have been a significant legal matter for the company.

Additionally, NCS Healthcare, Inc. was also involved in a securities litigation case that settled for approximately $100 million. This suggests that the company faced allegations or claims related to its securities or financial reporting, which ultimately resulted in a substantial settlement.

While the specific details of the legal proceedings are not fully known, the provided descriptions indicate that NCS Healthcare, Inc. has faced scrutiny and legal challenges in recent years. The company's involvement in these types of cases, particularly the $100 million securities litigation settlement, suggests that it has had to navigate complex legal and financial issues.

Overall, the summary of the available information paints a picture of NCS Healthcare, Inc. as a company that has encountered significant legal and regulatory challenges, likely impacting its operations and financial standing. However, without more detailed information, it is difficult to provide a comprehensive assessment of the company's current status or the long-term implications of these legal matters.</data>
    </node>
    <node id="46">
      <data key="d0">YBM MAGNEX INTERNATIONAL, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">30.0</data>
      <data key="d5">YBM Magnex International, Inc. is a company that has been involved in legal proceedings related to shareholder and securities litigation.

According to the information provided, YBM Magnex International, Inc. was involved in a shareholder litigation case. Additionally, the company was involved in a securities litigation case that settled for $85 million Canadian.

The details surrounding the shareholder litigation case are not explicitly stated, but the fact that the company was involved in such a case suggests that there were disputes or allegations made by shareholders against the company. The securities litigation case, on the other hand, appears to have been related to the company's financial reporting or disclosures, which led to a settlement of $85 million Canadian.

While the provided descriptions do not contain any contradictory information, they also do not provide a comprehensive overview of the company's history or the specific circumstances surrounding the legal proceedings. The summary is limited to the information directly stated in the descriptions, which focuses on the legal cases the company has been involved in.

Overall, YBM Magnex International, Inc. has faced legal challenges related to shareholder and securities litigation, resulting in a significant settlement in the securities case. However, the full context and details of these legal proceedings are not fully known based on the information provided.</data>
    </node>
    <node id="47">
      <data key="d0">NEW JERSEY COURT OF CHANCERY</data>
      <data key="d1">GEO</data>
      <data key="d2">25.0</data>
      <data key="d5">The New Jersey Court of Chancery is the court that presided over the Pamrapo Bancorp shareholder litigation case</data>
    </node>
    <node id="48">
      <data key="d0">UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA</data>
      <data key="d1">GEO</data>
      <data key="d2">25.0</data>
      <data key="d5">The United States District Court for the Eastern District of Pennsylvania presided over the YBM Magnex International, Inc. securities litigation case</data>
    </node>
    <node id="49">
      <data key="d0">DELAWARE COURT OF CHANCERY</data>
      <data key="d1" />
      <data key="d2">25.0</data>
      <data key="d5" />
    </node>
    <node id="50">
      <data key="d0">LAW360</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">12.0</data>
      <data key="d5">Law360 is a legal news publication where Ed Korsinsky published his analysis on mass arbitration reform.</data>
    </node>
    <node id="51">
      <data key="d0">MASS ARBITRATION</data>
      <data key="d1">EVENT</data>
      <data key="d2">12.0</data>
      <data key="d5">Mass arbitration is the focus of the reforms that Ed Korsinsky analyzed and advocated for in his Law360 article.</data>
    </node>
    <node id="52">
      <data key="d0">CHEN</data>
      <data key="d1">PERSON</data>
      <data key="d2">4.0</data>
      <data key="d5">Chen is a person involved in the Occam Networks, Inc. litigation</data>
    </node>
    <node id="53">
      <data key="d0">HOWARD-ANDERSON</data>
      <data key="d1">PERSON</data>
      <data key="d2">4.0</data>
      <data key="d5">Howard-Anderson is a person involved in the Occam Networks, Inc. litigation</data>
    </node>
    <node id="54">
      <data key="d0">WEIGARD</data>
      <data key="d1">PERSON</data>
      <data key="d2">23.0</data>
      <data key="d5">Weigard is a person involved in the Health Grades, Inc. litigation</data>
    </node>
    <node id="55">
      <data key="d0">HICKS</data>
      <data key="d1">PERSON</data>
      <data key="d2">23.0</data>
      <data key="d5">Hicks is a person involved in the Health Grades, Inc. litigation</data>
    </node>
    <node id="56">
      <data key="d0">STRINE</data>
      <data key="d1">PERSON</data>
      <data key="d2">25.0</data>
      <data key="d5">Strine is a person involved in the CNX Gas Corp. litigation</data>
    </node>
    <node id="57">
      <data key="d0">QUANTUMSCAPE CORPORATION</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">25.0</data>
      <data key="d5">QuantumScape Corporation is a company that was involved in a $47.5 million settlement</data>
    </node>
    <node id="58">
      <data key="d0">LOMA NEGRA INDUSTRIAL ARGENTINA SOCIEDAD ARGENTINA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">25.0</data>
      <data key="d5">Loma Negra Industrial Argentina Sociedad Argentina was involved in a $24.6 million settlement</data>
    </node>
    <node id="59">
      <data key="d0">CORCEPT THERAPEUTICS INCORPORATED</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company focused on the discovery and development of medications to treat severe endocrine, oncologic, metabolic, and neurological disorders. The company's primary product is Korlym (mifepristone), which is approved in the United States for the treatment of patients suffering from Cushing's syndrome.

Corcept Therapeutics Incorporated was founded with the goal of developing innovative therapies that modulate the effects of the hormone cortisol, which plays a crucial role in the body's stress response and is implicated in various medical conditions. The company's research and development efforts have led to the discovery and advancement of several drug candidates, with Korlym being the first to receive regulatory approval.

While Corcept Therapeutics Incorporated has achieved commercial success with Korlym, the company has also faced some challenges. In the past, the company was involved in a $14 million settlement, though the details of this settlement are not entirely clear from the information provided. Additionally, the company has been the subject of an investigation for possible securities fraud, though the outcome and specifics of this investigation are not known.

Despite these challenges, Corcept Therapeutics Incorporated remains committed to its mission of developing innovative therapies to address unmet medical needs. The company continues to invest in research and development, exploring new applications for its existing products and advancing its pipeline of drug candidates.

In summary, Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company focused on the development of medications to treat severe endocrine, oncologic, metabolic, and neurological disorders. While the company has achieved success with its lead product, Korlym, it has also faced some legal and regulatory challenges in the past. However, Corcept Therapeutics Incorporated remains dedicated to its mission of developing innovative therapies and continues to invest in research and development to address unmet medical needs.</data>
    </node>
    <node id="60">
      <data key="d0">BABCOCK &amp; WILCOX ENTERPRISES, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">25.0</data>
      <data key="d5">Babcock &amp; Wilcox Enterprises, Inc. was involved in a $9.5 million settlement</data>
    </node>
    <node id="61">
      <data key="d0">U.S. STEEL</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">25.0</data>
      <data key="d5">U.S. Steel was involved in a $40 million settlement</data>
    </node>
    <node id="62">
      <data key="d0">AQUA METALS, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">25.0</data>
      <data key="d5">Aqua Metals, Inc. was involved in a $7 million settlement</data>
    </node>
    <node id="63">
      <data key="d0">WIDEOPENWEST, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">25.0</data>
      <data key="d5">WideOpenWest, Inc. was involved in a $7.025 million settlement</data>
    </node>
    <node id="64">
      <data key="d0">HELIOS AND MATHESON ANALYTICS INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">25.0</data>
      <data key="d5">Helios and Matheson Analytics Inc. was involved in an $8.25 million settlement</data>
    </node>
    <node id="65">
      <data key="d0">ILLUMINA, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">25.0</data>
      <data key="d5">Illumina, Inc. was involved in a $13.85 million settlement</data>
    </node>
    <node id="66">
      <data key="d0">AVON PRODUCTS INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">25.0</data>
      <data key="d5">Avon Products Inc. was involved in a $14.5 million settlement</data>
    </node>
    <node id="67">
      <data key="d0">RONALD B. RUBIN</data>
      <data key="d1">PERSON</data>
      <data key="d2">25.0</data>
      <data key="d5">Ronald B. Rubin is a judge who praised the handling of a case</data>
    </node>
    <node id="68">
      <data key="d0">TIMOTHY S. DRISCOLL</data>
      <data key="d1">PERSON</data>
      <data key="d2">25.0</data>
      <data key="d5">Timothy S. Driscoll is a judge who praised the conduct of the legal profession in a case</data>
    </node>
    <node id="69">
      <data key="d0">ANDREW L. CARTER, JR.</data>
      <data key="d1">PERSON</data>
      <data key="d2">25.0</data>
      <data key="d5">Andrew L. Carter, Jr. is a judge who found the firm to be well-qualified to serve as Lead Counsel</data>
    </node>
    <node id="70">
      <data key="d0">ANALISA TORRES</data>
      <data key="d1">PERSON</data>
      <data key="d2">25.0</data>
      <data key="d5">Analisa Torres is a judge who noted the firm's "extensive experience" in securities litigation</data>
    </node>
    <node id="71">
      <data key="d0">BARRY TED MOSKOWITZ</data>
      <data key="d1">PERSON</data>
      <data key="d2">25.0</data>
      <data key="d5">Barry Ted Moskowitz is a judge who found the class counsel to be skilled and adequate to represent the settlement class</data>
    </node>
    <node id="72">
      <data key="d0">VISTAGEN THERAPEUTICS, INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">28.0</data>
      <data key="d5">VISTAGEN THERAPEUTICS, INC.

VISTAGEN THERAPEUTICS, INC. is a pharmaceutical company that has faced several challenges in recent years. 

According to the provided information, the company's Phase 3 trial for its drug fasedienol did not meet the primary endpoint for treating social anxiety disorder. This suggests that the drug was not as effective as expected in treating this condition.

Additionally, VISTAGEN THERAPEUTICS, INC. has been the subject of a securities class action lawsuit. The lawsuit was filed by Levi &amp; Korsinsky, a law firm that specializes in securities litigation. The nature of the lawsuit is not specified, but it indicates that the company has faced legal issues related to its securities or financial reporting.

The provided descriptions also mention that VISTAGEN THERAPEUTICS, INC. is a public company, meaning it is traded on a stock exchange and its shares are available for public investment. The fact that it was the subject of a securities class action lawsuit suggests that the company may have faced allegations of financial misconduct or misrepresentation, which could have impacted its stock price and shareholder value.

Overall, the information provided paints a picture of a pharmaceutical company that has faced setbacks in its drug development efforts and legal challenges related to its securities and financial reporting. While the specific details of the issues are not fully clear, it is evident that VISTAGEN THERAPEUTICS, INC. has encountered difficulties in its operations and has had to navigate complex legal and regulatory environments.</data>
    </node>
    <node id="73">
      <data key="d0">DRUG TRIAL</data>
      <data key="d1" />
      <data key="d2">28.0</data>
      <data key="d5" />
    </node>
    <node id="74">
      <data key="d0">MARCH 16 2026</data>
      <data key="d1">EVENT</data>
      <data key="d2">28.0</data>
      <data key="d5">Deadline for filing class action lawsuit against Vistagen Therapeutics, Inc. and Smart Digital Group Limited</data>
    </node>
    <node id="75">
      <data key="d0">SEC</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">27.0</data>
      <data key="d5">The U.S. Securities and Exchange Commission (SEC) is a government agency that regulates the securities industry</data>
    </node>
    <node id="76">
      <data key="d0">NASDAQ</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">27.0</data>
      <data key="d5">NASDAQ is a major stock exchange located in the United States. It is one of the world's largest stock exchanges, known for trading a wide range of securities, including stocks, bonds, and exchange-traded funds (ETFs).

NASDAQ is the stock exchange where Vistagen Therapeutics, Inc., a biopharmaceutical company, is listed. Vistagen Therapeutics is a clinical-stage biopharmaceutical company focused on developing new generation medicines for central nervous system (CNS) disorders. The company's pipeline includes several drug candidates in various stages of development, targeting conditions such as depression, social anxiety disorder, and Parkinson's disease.

In addition to Vistagen Therapeutics, NASDAQ is also the exchange where SDM Securities was traded. SDM Securities was a financial services firm that operated on the NASDAQ exchange, providing investment and trading services to its clients.

NASDAQ is known for its technology-focused listings, with many prominent technology companies, such as Apple, Microsoft, and Amazon, trading on the exchange. The exchange is also home to a diverse range of industries, including healthcare, consumer goods, and financial services.

Overall, NASDAQ is a significant player in the global financial markets, providing a platform for the trading of a wide variety of securities and serving as a hub for many publicly traded companies, including Vistagen Therapeutics and the now-defunct SDM Securities.</data>
    </node>
    <node id="77">
      <data key="d0">SDM SECURITIES</data>
      <data key="d1" />
      <data key="d2">27.0</data>
      <data key="d5" />
    </node>
    <node id="78">
      <data key="d0">KELLER V. TRONOX HOLDINGS PLC</data>
      <data key="d1">EVENT</data>
      <data key="d2">25.0</data>
      <data key="d5">Keller v. Tronox Holdings PLC is a putative federal securities class action lawsuit</data>
    </node>
    <node id="79">
      <data key="d0">LATOZINEMAB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">24.0</data>
      <data key="d5">Latozinemab (AL001) is a drug candidate being developed by Alector, Inc. for the treatment of frontotemporal dementia due to a progranulin gene mutation (FTD-GRN)</data>
    </node>
    <node id="80">
      <data key="d0">FRONTOTEMPORAL DEMENTIA DUE TO A PROGRANULIN GENE MUTATION (FTD-GRN)</data>
      <data key="d1">EVENT</data>
      <data key="d2">24.0</data>
      <data key="d5">The Phase 2 INFRONT-3 clinical trial evaluated latozinemab (AL001) in patients with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN)</data>
    </node>
    <node id="81">
      <data key="d0">ALECTOR, INC.</data>
      <data key="d1" />
      <data key="d2">24.0</data>
      <data key="d5" />
    </node>
    <node id="82">
      <data key="d0">PALISADE-3</data>
      <data key="d1">EVENT</data>
      <data key="d2">28.0</data>
      <data key="d5">PALISADE-3 is the Phase 3 clinical trial study of fasedienol, an investigational pherine candidate in development by Vistagen Therapeutics, Inc. for the acute treatment of social anxiety disorder. The PALISADE-3 study is evaluating the safety and efficacy of fasedienol in patients with social anxiety disorder.

Social anxiety disorder is a mental health condition characterized by intense fear or anxiety in social situations, such as interacting with others, public speaking, or performing in front of an audience. It can significantly impact a person's quality of life and ability to function in daily activities.

Fasedienol is a novel investigational drug that Vistagen Therapeutics is developing as a potential treatment for social anxiety disorder. The PALISADE-3 study is designed to assess the safety and efficacy of fasedienol in reducing the symptoms of social anxiety disorder in adult patients.

The study is a randomized, double-blind, placebo-controlled trial, which means that participants are randomly assigned to receive either the investigational drug or a placebo (a substance with no active ingredients), and neither the participants nor the researchers know who is receiving the actual drug. This study design helps to ensure the reliability and validity of the results.

The primary outcome measure of the PALISADE-3 study is the change in the Liebowitz Social Anxiety Scale (LSAS) score from baseline to the end of the treatment period. The LSAS is a widely used and validated assessment tool for evaluating the severity of social anxiety disorder symptoms.

Secondary outcome measures include changes in other clinical assessments, such as the Clinical Global Impression of Severity (CGI-S) scale, the Social Phobia Inventory (SPIN), and the Sheehan Disability Scale (SDS). These measures will provide a comprehensive evaluation of the impact of fasedienol on various aspects of social anxiety disorder.

The PALISADE-3 study is currently ongoing, and Vistagen Therapeutics expects to report the topline results in the coming months. If the study demonstrates the safety and efficacy of fasedienol in treating social anxiety disorder, it could potentially provide a new treatment option for individuals struggling with this debilitating condition.</data>
    </node>
    <node id="83">
      <data key="d0">GLOBE NEWSWIRE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">11.0</data>
      <data key="d5">The news wire service that published the announcement about the Vistagen Therapeutics lawsuit</data>
    </node>
    <node id="84">
      <data key="d0">FDA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">14.0</data>
      <data key="d5">The U.S. Food and Drug Administration is the regulatory agency that denied approval of Corcept's new drug application for relacorilant</data>
    </node>
    <node id="85">
      <data key="d0">GRACE</data>
      <data key="d1">EVENT</data>
      <data key="d2">16.0</data>
      <data key="d5">The GRACE drug trial was previously conducted by Corcept Therapeutics</data>
    </node>
    <node id="86">
      <data key="d0">GRADIENT</data>
      <data key="d1">EVENT</data>
      <data key="d2">16.0</data>
      <data key="d5">The GRADIENT drug trial was previously conducted by Corcept Therapeutics</data>
    </node>
    <node id="87">
      <data key="d0">RELACORILANT</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">Relacorilant is a drug candidate developed by Corcept Therapeutics for the treatment of hypertension secondary to hypercortisolism. It is a selective cortisol modulator in Corcept Therapeutics' portfolio of drug candidates.

Hypercortisolism, also known as Cushing's syndrome, is a condition characterized by excessive production of the hormone cortisol by the adrenal glands. This can lead to a range of health issues, including hypertension (high blood pressure), weight gain, diabetes, and other metabolic problems. Relacorilant is being developed by Corcept Therapeutics as a potential treatment option for the hypertension that can occur as a result of hypercortisolism.

As a selective cortisol modulator, Relacorilant is designed to regulate the activity of cortisol in the body, helping to manage the effects of excessive cortisol production. By targeting the underlying hormonal imbalance, Relacorilant aims to address the hypertension and other symptoms associated with Cushing's syndrome.

The development of Relacorilant by Corcept Therapeutics is part of the company's efforts to expand its portfolio of drug candidates for the treatment of various cortisol-related disorders. Corcept Therapeutics is a biopharmaceutical company focused on the discovery and development of drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders.

Overall, Relacorilant represents a promising drug candidate for the management of hypertension secondary to hypercortisolism, offering a potential new treatment option for individuals affected by this condition. The continued research and development of Relacorilant by Corcept Therapeutics will be important in determining its efficacy and safety as a therapeutic intervention.</data>
    </node>
    <node id="88">
      <data key="d0">KORLYM</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">
Korlym (mifepristone) is a medication marketed by Corcept Therapeutics for the treatment of patients suffering from Cushing's syndrome.</data>
    </node>
    <node id="89">
      <data key="d0">CUSHINGS SYNDROME</data>
      <data key="d1">EVENT</data>
      <data key="d2">16.0</data>
      <data key="d5">Cushing's syndrome is a hormonal disorder caused by excessive production of the hormone cortisol by the adrenal glands.</data>
    </node>
    <node id="90">
      <data key="d0">EXICORILANT</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">Exicorilant is a selective cortisol modulator in Corcept Therapeutics' portfolio of drug candidates.</data>
    </node>
    <node id="91">
      <data key="d0">DAZUCORILANT</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">Dazucorilant is a selective cortisol modulator in Corcept Therapeutics' portfolio of drug candidates.</data>
    </node>
    <node id="92">
      <data key="d0">MIRICORILANT</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">Miricorilant is a selective cortisol modulator in Corcept Therapeutics' portfolio of drug candidates.</data>
    </node>
    <node id="93">
      <data key="d0">FACTSET</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">FactSet is a financial data and software company that provides stock quotes</data>
    </node>
    <node id="94">
      <data key="d0">MORNINGSTAR</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">Morningstar is a financial services firm that provides stock quotes</data>
    </node>
    <node id="95">
      <data key="d0">S&amp;P CAPITAL IQ</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">16.0</data>
      <data key="d5">S&amp;P Capital IQ is a financial information and analytics company that provides stock quotes</data>
    </node>
    <node id="96">
      <data key="d0">E.L.F. BEAUTY, INC.</data>
      <data key="d1" />
      <data key="d2">26.0</data>
      <data key="d5" />
    </node>
    <node id="97">
      <data key="d0">NYSE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">26.0</data>
      <data key="d5">The New York Stock Exchange, where e.l.f. Beauty, Inc. is listed</data>
    </node>
    <node id="98">
      <data key="d0">CORCEPT</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">25.0</data>
      <data key="d5">Corcept is a public company that was investigated by Levi &amp; Korsinsky for possible securities fraud violations.</data>
    </node>
    <node id="99">
      <data key="d0">FASEDIENOL</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">28.0</data>
      <data key="d5">Fasedienol is an investigational pherine candidate developed by Vistagen Therapeutics, Inc. for the acute treatment of social anxiety disorder</data>
    </node>
    <node id="100">
      <data key="d0">HOPE-2 TRIAL</data>
      <data key="d1">EVENT</data>
      <data key="d2">14.0</data>
      <data key="d5">The HOPE-2 TRIAL was a Phase 2 clinical trial conducted by Capricor to evaluate the safety and efficacy of deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD).

The HOPE-2 trial was a Phase 2 clinical study that aimed to assess the safety and effectiveness of deramiocel, a cell therapy product developed by Capricor, in treating the cardiomyopathy (heart muscle disease) that often accompanies DMD. DMD is a rare and severe genetic disorder that primarily affects boys, causing progressive muscle weakness and degeneration.

The trial enrolled participants with DMD and cardiomyopathy to receive either deramiocel or a placebo (a non-active treatment) through intravenous infusion. The primary outcome measures of the study were to evaluate the safety and tolerability of deramiocel, as well as its potential to improve cardiac function and exercise capacity in the participants.

Deramiocel is a type of cell therapy that utilizes cardiosphere-derived cells (CDCs), which are extracted from a patient's own heart tissue and then expanded in the laboratory. The goal of this approach is to harness the regenerative and reparative properties of these cells to potentially improve cardiac function and mitigate the progression of cardiomyopathy in individuals with DMD.

The HOPE-2 trial was designed to build upon the promising results observed in the earlier HOPE-Duchenne trial, which had demonstrated the safety and potential efficacy of deramiocel in a smaller cohort of DMD patients with cardiomyopathy.

By conducting the larger-scale HOPE-2 trial, Capricor aimed to further investigate the therapeutic potential of deramiocel and its ability to address the significant unmet medical need in the management of DMD-associated cardiomyopathy. The comprehensive data collected from this trial will help inform the future development and potential regulatory approval of deramiocel as a novel treatment option for this debilitating condition.

The HOPE-2 trial represents an important step forward in the ongoing efforts to improve the quality of life and clinical outcomes for individuals living with Duchenne muscular dystrophy and the associated cardiac complications.</data>
    </node>
    <node id="101">
      <data key="d0">BIOLOGICS LICENSE APPLICATION (BLA)</data>
      <data key="d1">EVENT</data>
      <data key="d2">14.0</data>
      <data key="d5">The Biologics License Application (BLA) is a request for permission to introduce, or deliver for introduction, a biologic product into interstate commerce</data>
    </node>
    <node id="102">
      <data key="d0">TSLA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">25.0</data>
      <data key="d5">TSLA is the stock ticker symbol for Tesla, the American electric vehicle and clean energy company.</data>
    </node>
    <node id="103">
      <data key="d0">COMPLETE RESPONSE LETTER (CRL)</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">14.0</data>
      <data key="d5">A Complete Response Letter is a communication from the FDA to an applicant regarding a Biologics License Application, indicating that the review cycle for the application is complete and the application is not ready for approval</data>
    </node>
    <node id="104">
      <data key="d0">VISTAGEN</data>
      <data key="d1" />
      <data key="d2">11.0</data>
      <data key="d5" />
    </node>
    <edge id="e0" source="0" target="6">
      <data key="d3">43.0</data>
      <data key="d4">LLP law firm...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP is a law firm based in the United States, and Joseph E. Levi is an attorney who works there. According to the information provided, Joseph E. Levi is the founding partner of Levi &amp; Korsinsky, LLP and a central figure in shaping and managing the firm's securities litigation practice.

Joseph E. Levi is involved in a class action lawsuit against Vistagen Therapeutics, Inc. as an attorney at Levi &amp; Korsinsky, LLP. The firm is known for its work in securities litigation, and Levi plays a key role in this area of the firm's practice.

In summary, Levi &amp; Korsinsky, LLP is a law firm that specializes in securities litigation, and Joseph E. Levi is the founding partner of the firm and a central figure in its securities litigation practice. Levi is currently involved in a class action lawsuit against Vistagen Therapeutics, Inc. as an attorney at the firm.</data>
    </edge>
    <edge id="e1" source="0" target="1">
      <data key="d3">16.0</data>
      <data key="d4">represented former shareholders...</data>
      <data key="d6">Levi &amp; Korsinsky represented the former shareholders of Occam Networks, Inc. in litigation challenging the company's merger with Calix, Inc., ultimately recovering $35 million for the shareholders.</data>
    </edge>
    <edge id="e2" source="0" target="3">
      <data key="d3">16.0</data>
      <data key="d4">represented Health Grades,...</data>
      <data key="d6">Levi &amp; Korsinsky represented Health Grades, Inc.'s shareholders and successfully demonstrated that the defendants had likely breached their fiduciary duties, leading to a favorable settlement.</data>
    </edge>
    <edge id="e3" source="0" target="5">
      <data key="d3">9.0</data>
      <data key="d4">played prominent role...</data>
      <data key="d6">Levi &amp; Korsinsky played a prominent role in the matter of In re CNX Gas Corp. Shareholders Litigation, in which plaintiffs recovered a common fund of over $42.7 million for stockholders.</data>
    </edge>
    <edge id="e4" source="0" target="7">
      <data key="d3">8.0</data>
      <data key="d4">obtained preliminary injunction...</data>
      <data key="d6">Levi &amp; Korsinsky obtained a preliminary injunction against the merger of Occam Networks and Calix due to material misrepresentations and omissions in the proxy statement.</data>
    </edge>
    <edge id="e5" source="0" target="8">
      <data key="d3">8.0</data>
      <data key="d4">successfully demonstrated Delaware...</data>
      <data key="d6">Levi &amp; Korsinsky successfully demonstrated to the Delaware Court of Chancery that the defendants had likely breached their fiduciary duties to Health Grades' shareholders by failing to maximize value.</data>
    </edge>
    <edge id="e6" source="0" target="9">
      <data key="d3">1.0</data>
      <data key="d4">played prominent role...</data>
      <data key="d6">Levi &amp; Korsinsky played a prominent role in the matter of In re CNX Gas Corp. Shareholders Litigation, in which plaintiffs recovered a common fund of over $42.7 million for stockholders.</data>
    </edge>
    <edge id="e7" source="10" target="12">
      <data key="d3">16.0</data>
      <data key="d4">filed class action...</data>
      <data key="d6">Levi &amp; Korsinsky has filed a class action securities lawsuit against Capricor Therapeutics, Inc. on behalf of shareholders who were adversely affected by alleged securities fraud between October 9, 2024 and July 10, 2025.</data>
    </edge>
    <edge id="e8" source="10" target="11">
      <data key="d3">10.0</data>
      <data key="d4">Capricor's Biologics License...</data>
      <data key="d6">The FDA denied Capricor's Biologics License Application (BLA) for its lead drug candidate deramiocel, citing a lack of substantial evidence of effectiveness and the need for additional clinical data.</data>
    </edge>
    <edge id="e9" source="10" target="13">
      <data key="d3">26.0</data>
      <data key="d4">biopharmaceutical company focused...</data>
      <data key="d6">Capricor Therapeutics, Inc. is a biopharmaceutical company focused on the development of novel cell and exosome-based therapies for the treatment of various diseases and medical conditions. The company's lead cell therapy candidate is deramiocel, which is being developed for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD).

Deramiocel is a cell therapy drug that is being developed by Capricor Therapeutics as a potential treatment for the cardiomyopathy, or heart muscle disease, that often accompanies Duchenne muscular dystrophy. DMD is a rare and severe genetic disorder that primarily affects young boys, causing progressive muscle weakness and degeneration.

The cardiomyopathy associated with DMD can lead to heart failure and is a major cause of morbidity and mortality in these patients. Deramiocel is designed to address this complication by using a proprietary population of cardiac-derived cells to potentially regenerate and repair the damaged heart muscle.

Capricor Therapeutics is currently conducting clinical trials to evaluate the safety and efficacy of deramiocel in DMD patients with cardiomyopathy. The company's goal is to develop a cell therapy that can improve cardiac function, reduce the risk of heart failure, and ultimately improve the quality of life for individuals living with this devastating disease.

The development of deramiocel is a key focus for Capricor Therapeutics, as the company believes it has the potential to address a significant unmet medical need in the DMD patient population. By leveraging its expertise in cell-based therapies, the company is working to advance this innovative treatment approach and provide new hope for those affected by the cardiac complications of Duchenne muscular dystrophy.</data>
    </edge>
    <edge id="e10" source="13" target="14">
      <data key="d3">19.0</data>
      <data key="d4">cell therapy drug...</data>
      <data key="d6">Deramiocel is a cell therapy drug being developed by Capricor Therapeutics for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). DMD is a rare and severe genetic disorder characterized by progressive muscle degeneration and weakness, primarily affecting young boys.

Deramiocel is a novel therapeutic approach that aims to address the cardiomyopathy, or heart muscle disease, that often accompanies DMD. Cardiomyopathy is a common and serious complication of DMD, as the progressive weakening of the heart muscle can lead to heart failure and other life-threatening cardiac issues.

The development of Deramiocel is based on the use of cardiosphere-derived cells (CDCs), which are a type of stem cell that can differentiate into various cardiac cell types. The goal of Deramiocel is to deliver these CDCs to the damaged heart muscle, where they can potentially regenerate and repair the tissue, improving cardiac function and overall health outcomes for individuals with DMD.

Capricor Therapeutics, the biopharmaceutical company behind Deramiocel, is currently conducting clinical trials to evaluate the safety and efficacy of this cell therapy in DMD patients with cardiomyopathy. The available descriptions indicate that Deramiocel is being developed specifically as a treatment for the cardiomyopathy associated with DMD, highlighting the unmet need for effective therapies to address this debilitating aspect of the disease.

By summarizing the available information, it is clear that Deramiocel represents a promising and targeted approach to addressing the cardiac complications of Duchenne muscular dystrophy. The development of this cell therapy by Capricor Therapeutics underscores the ongoing efforts to improve the quality of life and long-term prognosis for individuals living with this devastating genetic disorder.</data>
    </edge>
    <edge id="e11" source="6" target="16">
      <data key="d3">36.0</data>
      <data key="d4">attorney Levi...</data>
      <data key="d6">Joseph E. Levi is an attorney at Levi &amp; Korsinsky LLP.</data>
    </edge>
    <edge id="e12" source="15" target="16">
      <data key="d3">28.0</data>
      <data key="d4">attorney Levi...</data>
      <data key="d6">Ed Korsinsky is an attorney at Levi &amp; Korsinsky LLP.</data>
    </edge>
    <edge id="e13" source="16" target="17">
      <data key="d3">8.0</data>
      <data key="d4">Action Services ranked...</data>
      <data key="d6">ISS Securities Class Action Services has ranked Levi &amp; Korsinsky LLP as one of the top securities litigation firms in the United States for seven years in a row.</data>
    </edge>
    <edge id="e14" source="16" target="18">
      <data key="d3">1.0</data>
      <data key="d4">LLP published press...</data>
      <data key="d6">Levi &amp; Korsinsky LLP published a press release on ACCESS Newswire.</data>
    </edge>
    <edge id="e15" source="15" target="12">
      <data key="d3">34.0</data>
      <data key="d4">co-founder managing partner...</data>
      <data key="d6">Ed Korsinsky is the co-founder and managing partner of the law firm Levi &amp; Korsinsky, which he established in 2003 with Joe Levi. Levi &amp; Korsinsky is a plaintiff securities firm that represents shareholders in various legal matters.

As an attorney at Levi &amp; Korsinsky, Ed Korsinsky has represented the shareholders of Vistagen Therapeutics, a biopharmaceutical company. Korsinsky's work with Levi &amp; Korsinsky involves advocating for the rights and interests of shareholders in legal disputes and proceedings.

Levi &amp; Korsinsky has a track record of successfully representing shareholders in class action lawsuits and other legal actions against public companies. The firm's expertise lies in securities litigation, helping investors recover losses and hold companies accountable for financial misconduct or misrepresentations.

Through his leadership at Levi &amp; Korsinsky, Ed Korsinsky has established the firm as a prominent player in the field of shareholder rights and securities law. The firm's focus on protecting the interests of investors has earned it a reputation for aggressive and effective legal representation.

In his role as the co-founder and managing partner of Levi &amp; Korsinsky, Korsinsky oversees the firm's operations, strategic direction, and the work of its team of experienced attorneys. His extensive knowledge of securities law and his commitment to advocating for shareholder rights have been instrumental in the firm's success.

Overall, Ed Korsinsky's work at Levi &amp; Korsinsky demonstrates his dedication to protecting the interests of investors and holding public companies accountable for their actions. Through his leadership and legal expertise, Korsinsky has positioned the firm as a formidable force in the field of shareholder rights and securities litigation.</data>
    </edge>
    <edge id="e16" source="15" target="22">
      <data key="d3">16.0</data>
      <data key="d4">strong background interest...</data>
      <data key="d6">Ed Korsinsky has a strong background and interest in technology, having grown up in a technologically-inclined household and developing software and hardware as a teenager. He has leveraged this expertise to build the CORE platform that differentiates Levi &amp; Korsinsky from its competitors.</data>
    </edge>
    <edge id="e17" source="15" target="23">
      <data key="d3">7.0</data>
      <data key="d4">acquired one first...</data>
      <data key="d6">Ed Korsinsky's father acquired one of the first IBM PCs and used it for various technology projects, which Korsinsky helped with as a child.</data>
    </edge>
    <edge id="e18" source="15" target="24">
      <data key="d3">1.0</data>
      <data key="d4">worked developing facial...</data>
      <data key="d6">Ed Korsinsky's father worked on developing facial recognition software and hardware, which Korsinsky helped with as a child.</data>
    </edge>
    <edge id="e19" source="19" target="12">
      <data key="d3">26.0</data>
      <data key="d4">Korsinsky CORE...</data>
      <data key="d6">CORE and Levi &amp; Korsinsky

CORE is a technology platform developed by the law firm Levi &amp; Korsinsky to enable their clients to track case developments and recover damages in a more efficient and transparent manner. The CORE platform was created by the attorneys at Levi &amp; Korsinsky to facilitate the seamless input of court developments and provide real-time updates to their clients.

Levi &amp; Korsinsky is a law firm that specializes in class action lawsuits and securities litigation. The firm has a team of experienced attorneys who have helped develop the CORE technology platform to streamline the process of tracking and managing legal cases. The CORE platform allows Levi &amp; Korsinsky's clients to access up-to-date information on the status of their cases, including court filings, rulings, and settlement negotiations.

The CORE platform is designed to improve the efficiency and transparency of the legal process for Levi &amp; Korsinsky's clients. By providing real-time updates and easy access to case information, the platform helps clients stay informed and make more informed decisions about their legal matters. The platform also allows Levi &amp; Korsinsky's attorneys to work more effectively, as they can quickly access and update case information without having to manually track and manage multiple sources of information.

Overall, the CORE technology platform developed by Levi &amp; Korsinsky is a valuable tool that helps the firm's clients navigate the complex world of class action lawsuits and securities litigation. By leveraging technology to streamline the legal process, Levi &amp; Korsinsky is able to provide its clients with a more efficient and transparent experience, ultimately helping them to recover the damages they are entitled to.</data>
    </edge>
    <edge id="e20" source="20" target="12">
      <data key="d3">16.0</data>
      <data key="d4">represented clients securities...</data>
      <data key="d6">Levi &amp; Korsinsky represented clients in a securities litigation case against E-Trade Financial Corp., recovering $79 million.</data>
    </edge>
    <edge id="e21" source="21" target="12">
      <data key="d3">9.0</data>
      <data key="d4">indemnified Google Inc....</data>
      <data key="d6">Levi &amp; Korsinsky indemnified Google Inc. investors for up to $522 million in losses in a corporate governance matter.</data>
    </edge>
    <edge id="e22" source="25" target="12">
      <data key="d3">7.0</data>
      <data key="d4">partner Levi...</data>
      <data key="d6">Nick Porritt is a partner at Levi &amp; Korsinsky who began his legal career in New Zealand</data>
    </edge>
    <edge id="e23" source="26" target="12">
      <data key="d3">7.0</data>
      <data key="d4">partner Levi...</data>
      <data key="d6">Greg Nespole is a partner at Levi &amp; Korsinsky who previously defended suspects in organized crime and racketeering cases before moving into securities litigation</data>
    </edge>
    <edge id="e24" source="27" target="12">
      <data key="d3">8.0</data>
      <data key="d4">representing shareholders lawsuits...</data>
      <data key="d6">Levi &amp; Korsinsky is representing shareholders in lawsuits against AmerisourceBergen over the opioid crisis</data>
    </edge>
    <edge id="e25" source="28" target="12">
      <data key="d3">1.0</data>
      <data key="d4">representing shareholders lawsuits...</data>
      <data key="d6">Levi &amp; Korsinsky is representing shareholders in lawsuits against Walmart over the opioid crisis, as Walmart pharmacies filled prescriptions for opioid painkillers</data>
    </edge>
    <edge id="e26" source="12" target="30">
      <data key="d3">7.0</data>
      <data key="d4">implemented policies create...</data>
      <data key="d6">Levi &amp; Korsinsky has implemented policies to create a more fun and accommodating workplace for its employees</data>
    </edge>
    <edge id="e27" source="12" target="29">
      <data key="d3">1.0</data>
      <data key="d4">co-founder Levi Korsinsky...</data>
      <data key="d6">Korsinsky is a co-founder of Levi &amp; Korsinsky and has shaped the firm's approach to employee culture</data>
    </edge>
    <edge id="e28" source="31" target="0">
      <data key="d3">40.0</data>
      <data key="d4">Managing Partner Co-Founder...</data>
      <data key="d6">Eduard Korsinsky is the Managing Partner and Co-Founder of Levi &amp; Korsinsky LLP, a national securities firm that has recovered billions of dollars for investors.</data>
    </edge>
    <edge id="e29" source="31" target="32">
      <data key="d3">16.0</data>
      <data key="d4">recovered million investors...</data>
      <data key="d6">Eduard Korsinsky's firm recovered $79 million for investors of E-Trade Financial Corporation in a securities case.</data>
    </edge>
    <edge id="e30" source="31" target="33">
      <data key="d3">16.0</data>
      <data key="d4">obtained payment ladder...</data>
      <data key="d6">Eduard Korsinsky's firm obtained a payment ladder indemnifying investors of Google, Inc. up to $8 billion in losses on a ground-breaking corporate governance case.</data>
    </edge>
    <edge id="e31" source="31" target="37">
      <data key="d3">36.0</data>
      <data key="d4">co-founder founder...</data>
      <data key="d6">Eduard Korsinsky is a co-founder and founder of CORE Monitoring Systems LLC, a technology platform designed to assist institutional clients more effectively monitor their investment portfolios and maximize recoveries on securities litigation.

CORE Monitoring Systems LLC is a company that provides a technology platform to help institutional clients better monitor their investment portfolios and maximize recoveries on securities litigation. The company was co-founded and founded by Eduard Korsinsky.

The descriptions provided indicate that Eduard Korsinsky is a key figure in the establishment and leadership of CORE Monitoring Systems LLC. The company's primary focus is to offer a technological solution that enables institutional investors to more effectively oversee their investment portfolios and optimize their recoveries from securities-related legal proceedings.

While the descriptions contain some minor variations in the wording used to describe Korsinsky's role (co-founder vs. founder), the overall information is consistent and complementary. There are no apparent contradictions in the data provided.

In summary, Eduard Korsinsky is a co-founder and founder of CORE Monitoring Systems LLC, a technology company that aims to assist institutional clients in improving their investment portfolio monitoring and maximizing their recoveries from securities litigation. The company's primary focus is to provide a technological platform to support these objectives for its institutional clientele.</data>
    </edge>
    <edge id="e32" source="31" target="38">
      <data key="d3">29.0</data>
      <data key="d4">individual who received...</data>
      <data key="d6">Eduard Korsinsky is an individual who received his Master of Laws (LL.M.) degree in Taxation from the New York University School of Law. The provided descriptions indicate that Korsinsky obtained his LL.M. from NYU School of Law in 1997.

The descriptions are consistent in stating that Korsinsky received an LL.M. degree from the New York University School of Law, with some minor variations in the exact wording used to describe the degree. The descriptions all agree that the degree was in the field of Taxation.

To summarize the key information:

Eduard Korsinsky is an individual who received his Master of Laws (LL.M.) degree in Taxation from the New York University School of Law in 1997.</data>
    </edge>
    <edge id="e33" source="31" target="39">
      <data key="d3">29.0</data>
      <data key="d4">individual who received...</data>
      <data key="d6">Eduard Korsinsky is an individual who received a Juris Doctor (J.D.) degree from Brooklyn Law School. According to the provided descriptions, Korsinsky graduated from Brooklyn Law School in 1995. The descriptions consistently state that Korsinsky obtained his J.D. from Brooklyn Law School, though they differ slightly in the specific year of graduation, with two descriptions indicating 1995 and one simply stating that he received his J.D. from the institution.

Brooklyn Law School is the law school that Korsinsky attended and from which he received his J.D. degree. The descriptions do not provide any additional details about Brooklyn Law School beyond the fact that it is the institution from which Korsinsky obtained his law degree.

In summary, Eduard Korsinsky is an individual who graduated from Brooklyn Law School with a Juris Doctor degree in 1995. The provided descriptions offer a consistent account of Korsinsky's educational background, with minor variations in the specific year of his graduation from the law school.</data>
    </edge>
    <edge id="e34" source="31" target="40">
      <data key="d3">10.0</data>
      <data key="d4">individual who received...</data>
      <data key="d6">Eduard Korsinsky is an individual who received his Bachelor of Science (B.S.) degree in Accounting from Brooklyn College. According to the provided descriptions, Korsinsky graduated summa cum laude from Brooklyn College in 1992 with his B.S. in Accounting.

The descriptions consistently state that Korsinsky received his B.S. degree from Brooklyn College, and that he graduated with the highest academic distinction of summa cum laude. The only minor difference in the descriptions is the exact wording used to convey this information, but the core facts remain the same.

Brooklyn College is the educational institution from which Korsinsky obtained his undergraduate degree in Accounting. The descriptions do not provide any additional details about Brooklyn College beyond its role in Korsinsky's educational background.

In summary, Eduard Korsinsky graduated summa cum laude from Brooklyn College in 1992 with a Bachelor of Science degree in Accounting.</data>
    </edge>
    <edge id="e35" source="34" target="0">
      <data key="d3">32.0</data>
      <data key="d4">prominent electric vehicle...</data>
      <data key="d6">Tesla is a prominent electric vehicle manufacturer that has been the subject of several high-profile securities matters. Levi &amp; Korsinsky LLP, a law firm specializing in securities litigation, has served as lead counsel in some of the largest securities cases involving Tesla.

The descriptions provided indicate that Levi &amp; Korsinsky LLP has played a significant role in representing investors in securities cases against Tesla. The firm has been involved in the "largest securities matters" involving the company, suggesting that they have handled major legal disputes and class actions related to Tesla's financial disclosures, stock performance, or other securities-related issues.

While the descriptions provided are slightly contradictory in their wording, with one stating that Levi &amp; Korsinsky LLP serves as lead counsel in "some of the largest securities matters" and the other stating that they serve as lead counsel in "the largest securities matters," the overall message is consistent. The firm has been a prominent player in securities litigation involving Tesla, representing investors in high-profile cases.

It is important to note that the specific details of the cases and the nature of the allegations against Tesla are not provided in the given information. However, the fact that Levi &amp; Korsinsky LLP has been involved in the "largest securities matters" suggests that these cases may have had significant financial and legal implications for both Tesla and its investors.

In summary, Tesla, the electric vehicle manufacturer, has been the subject of several high-profile securities matters, and Levi &amp; Korsinsky LLP, a law firm specializing in securities litigation, has served as lead counsel in some of the largest of these cases. The firm's involvement in these matters indicates that they have played a significant role in representing investors in legal disputes and class actions related to Tesla's securities.</data>
    </edge>
    <edge id="e36" source="35" target="0">
      <data key="d3">32.0</data>
      <data key="d4">LEVI KORSINSKY, LLP...</data>
      <data key="d6">US STEEL and LEVI &amp; KORSINSKY, LLP

US Steel is a major American steel company that has been involved in several significant securities matters. Levi &amp; Korsinsky LLP, a law firm, has served as lead counsel in some of the largest securities cases involving US Steel.

The descriptions provided indicate that Levi &amp; Korsinsky LLP has played a prominent role in representing clients in securities-related litigation against US Steel. The firm has been involved in the "largest securities matters" involving the steel company, suggesting that it has handled high-profile and impactful cases on behalf of its clients.

While the descriptions are slightly contradictory in their wording, with one stating that Levi &amp; Korsinsky LLP serves as lead counsel in "some of the largest securities matters" and the other stating that it serves as lead counsel in "the largest securities matters," the overall message is consistent. The law firm has been a key player in securities litigation against US Steel, taking on significant and influential cases on behalf of its clients.

In summary, US Steel, a major American steel company, has been involved in substantial securities-related legal matters, and the law firm Levi &amp; Korsinsky LLP has served as the lead counsel in these high-profile cases, representing clients in the largest and most significant securities litigation involving US Steel.</data>
    </edge>
    <edge id="e37" source="36" target="0">
      <data key="d3">32.0</data>
      <data key="d4">Levi Korsinsky, LLP...</data>
      <data key="d6">Kraft Heinz and Levi &amp; Korsinsky, LLP

Kraft Heinz is a major food and beverage company that has been involved in some of the largest securities matters, with Levi &amp; Korsinsky, LLP serving as the lead counsel. Levi &amp; Korsinsky LLP is a law firm that specializes in securities litigation and has played a significant role in representing Kraft Heinz in these matters.

The descriptions provided indicate that Levi &amp; Korsinsky LLP has served as the lead counsel in the largest securities matters involving Kraft Heinz. This suggests that the law firm has been instrumental in handling the company's most significant legal challenges related to securities and financial reporting.

While the descriptions do not provide specific details about the nature of the securities matters or the outcomes of the litigation, they highlight the close working relationship between Kraft Heinz and Levi &amp; Korsinsky LLP. The law firm's role as lead counsel in these matters suggests that it has a deep understanding of Kraft Heinz's business and the legal issues it faces.

Overall, the summary indicates that Kraft Heinz, a prominent food and beverage company, has relied on the expertise and legal representation of Levi &amp; Korsinsky LLP in navigating some of its most significant securities-related challenges. The law firm's involvement as lead counsel in these matters underscores its reputation and capabilities in the field of securities litigation.</data>
    </edge>
    <edge id="e38" source="41" target="0">
      <data key="d3">8.0</data>
      <data key="d4">LLP represented Pamrapo...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented Pamrapo Bancorp shareholders in a litigation case</data>
    </edge>
    <edge id="e39" source="21" target="0">
      <data key="d3">8.0</data>
      <data key="d4">LLP represented Google...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented Google Inc. shareholders in a litigation case regarding its Class C stock</data>
    </edge>
    <edge id="e40" source="42" target="0">
      <data key="d3">8.0</data>
      <data key="d4">LLP represented M.D.C....</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented M.D.C. Holdings, Inc. shareholders in a "say on pay" voting litigation case</data>
    </edge>
    <edge id="e41" source="43" target="0">
      <data key="d3">8.0</data>
      <data key="d4">LLP represented Technologies,...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented i2 Technologies, Inc. shareholders in a litigation case challenging asset sales</data>
    </edge>
    <edge id="e42" source="44" target="0">
      <data key="d3">8.0</data>
      <data key="d4">LLP represented Beazer...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented Beazer Homes shareholders in a litigation case regarding executive compensation</data>
    </edge>
    <edge id="e43" source="45" target="0">
      <data key="d3">8.0</data>
      <data key="d4">LLP represented NCS...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented NCS Healthcare, Inc. shareholders in a securities litigation case that settled for approximately $100 million</data>
    </edge>
    <edge id="e44" source="46" target="0">
      <data key="d3">1.0</data>
      <data key="d4">LLP represented YBM...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented YBM Magnex International, Inc. shareholders in a securities litigation case that settled for $85 million Canadian</data>
    </edge>
    <edge id="e45" source="0" target="49">
      <data key="d3">8.0</data>
      <data key="d4">LLP represented clients...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented clients in several shareholder litigation cases in the Delaware Court of Chancery</data>
    </edge>
    <edge id="e46" source="0" target="47">
      <data key="d3">8.0</data>
      <data key="d4">LLP represented clients...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented clients in a shareholder litigation case in the New Jersey Court of Chancery</data>
    </edge>
    <edge id="e47" source="0" target="48">
      <data key="d3">1.0</data>
      <data key="d4">LLP represented clients...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented clients in a securities litigation case in the United States District Court for the Eastern District of Pennsylvania</data>
    </edge>
    <edge id="e48" source="0" target="15">
      <data key="d3">45.0</data>
      <data key="d4">comprehensive summary data...</data>
      <data key="d6">Here is a comprehensive summary of the data provided:

Levi &amp; Korsinsky, LLP is a law firm, and Ed Korsinsky is one of its key partners. Korsinsky is a founding partner and managing partner of the firm, which he co-founded and leads. He is an attorney at Levi &amp; Korsinsky, LLP and is involved in the class action lawsuit against Vistagen Therapeutics, Inc.

The descriptions provided indicate that Ed Korsinsky holds several important roles within Levi &amp; Korsinsky, LLP. He is a founding partner, a managing partner, and a leading attorney at the firm. Korsinsky co-founded the law firm and currently leads it as the managing partner. 

In addition to his leadership roles, Korsinsky is also actively involved in the firm's legal work, as evidenced by his participation in the class action lawsuit against Vistagen Therapeutics, Inc. This suggests that Korsinsky is not only a senior figure within the firm, but also a practicing attorney who takes on significant cases.

Overall, the data paints a picture of Ed Korsinsky as a prominent and influential figure within Levi &amp; Korsinsky, LLP. He is a founding partner, managing partner, and lead attorney at the firm, which he co-founded and continues to lead. Korsinsky's involvement in high-profile legal matters, such as the class action lawsuit against Vistagen Therapeutics, further underscores his importance and influence within the law firm.</data>
    </edge>
    <edge id="e49" source="0" target="50">
      <data key="d3">8.0</data>
      <data key="d4">LLP featured...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP was featured in the legal news publication Law360 through Ed Korsinsky's analysis on mass arbitration reform.</data>
    </edge>
    <edge id="e50" source="50" target="15">
      <data key="d3">16.0</data>
      <data key="d4">analysis mass arbitration...</data>
      <data key="d6">Ed Korsinsky published an analysis on mass arbitration reform in the legal news publication Law360.</data>
    </edge>
    <edge id="e51" source="15" target="51">
      <data key="d3">1.0</data>
      <data key="d4">analysis advocating justice-centered...</data>
      <data key="d6">Ed Korsinsky published an analysis advocating for justice-centered reforms in mass arbitration.</data>
    </edge>
    <edge id="e52" source="32" target="0">
      <data key="d3">16.0</data>
      <data key="d4">LLP recovered million...</data>
      <data key="d6">Levi &amp; Korsinsky LLP recovered $79 million for investors in a securities case against E-Trade Financial Corporation.</data>
    </edge>
    <edge id="e53" source="33" target="0">
      <data key="d3">16.0</data>
      <data key="d4">LLP achieved payment...</data>
      <data key="d6">Levi &amp; Korsinsky LLP achieved a payment ladder indemnifying investors of Google, Inc. up to $8 billion in losses on a ground-breaking corporate governance case.</data>
    </edge>
    <edge id="e54" source="21" target="6">
      <data key="d3">8.0</data>
      <data key="d4">lead co-lead counsel...</data>
      <data key="d6">Joseph E. Levi was lead or co-lead counsel in a case involving Google Inc.</data>
    </edge>
    <edge id="e55" source="42" target="6">
      <data key="d3">8.0</data>
      <data key="d4">lead co-lead counsel...</data>
      <data key="d6">Joseph E. Levi was lead or co-lead counsel in a case involving M.D.C. Holdings, Inc.</data>
    </edge>
    <edge id="e56" source="43" target="6">
      <data key="d3">8.0</data>
      <data key="d4">lead co-lead counsel...</data>
      <data key="d6">Joseph E. Levi was lead or co-lead counsel in a case involving i2 Technologies, Inc.</data>
    </edge>
    <edge id="e57" source="44" target="6">
      <data key="d3">8.0</data>
      <data key="d4">lead co-lead counsel...</data>
      <data key="d6">Joseph E. Levi was lead or co-lead counsel in a case involving Beazer Homes</data>
    </edge>
    <edge id="e58" source="45" target="6">
      <data key="d3">8.0</data>
      <data key="d4">lead co-lead counsel...</data>
      <data key="d6">Joseph E. Levi was lead or co-lead counsel in a case involving NCS Healthcare, Inc.</data>
    </edge>
    <edge id="e59" source="46" target="6">
      <data key="d3">8.0</data>
      <data key="d4">lead co-lead counsel...</data>
      <data key="d6">Joseph E. Levi was lead or co-lead counsel in a case involving YBM Magnex International, Inc.</data>
    </edge>
    <edge id="e60" source="6" target="41">
      <data key="d3">8.0</data>
      <data key="d4">lead co-lead counsel...</data>
      <data key="d6">Joseph E. Levi was lead or co-lead counsel in a case involving Pamrapo Bancorp</data>
    </edge>
    <edge id="e61" source="6" target="1">
      <data key="d3">8.0</data>
      <data key="d4">lead co-lead counsel...</data>
      <data key="d6">Joseph E. Levi was lead or co-lead counsel in a case involving Occam Networks, Inc.</data>
    </edge>
    <edge id="e62" source="6" target="2">
      <data key="d3">8.0</data>
      <data key="d4">lead co-lead counsel...</data>
      <data key="d6">Joseph E. Levi was lead or co-lead counsel in a case involving Calix, Inc.</data>
    </edge>
    <edge id="e63" source="6" target="3">
      <data key="d3">8.0</data>
      <data key="d4">lead co-lead counsel...</data>
      <data key="d6">Joseph E. Levi was lead or co-lead counsel in a case involving Health Grades, Inc.</data>
    </edge>
    <edge id="e64" source="6" target="4">
      <data key="d3">8.0</data>
      <data key="d4">lead co-lead counsel...</data>
      <data key="d6">Joseph E. Levi was lead or co-lead counsel in a case involving Vestar Capital Partners, L.P.</data>
    </edge>
    <edge id="e65" source="6" target="5">
      <data key="d3">1.0</data>
      <data key="d4">lead co-lead counsel...</data>
      <data key="d6">Joseph E. Levi was lead or co-lead counsel in a case involving CNX Gas Corp.</data>
    </edge>
    <edge id="e66" source="6" target="0">
      <data key="d3">19.0</data>
      <data key="d4">managing partner...</data>
      <data key="d6">Joseph E. Levi is a managing partner at Levi &amp; Korsinsky, LLP, a law firm that specializes in representing investors in securities litigation. Levi is an experienced attorney who has been involved in numerous high-profile cases, including the Capricor Therapeutics lawsuit.

Levi &amp; Korsinsky, LLP is a law firm that has a reputation for aggressively pursuing legal action on behalf of investors who have been the victims of corporate fraud or other misconduct. The firm has a team of experienced attorneys who are dedicated to protecting the rights of investors and ensuring that they receive the compensation they are entitled to.

In the Capricor Therapeutics lawsuit, Joseph E. Levi is representing investors who allege that the company made false and misleading statements about the development of its experimental drug for the treatment of Duchenne muscular dystrophy. The lawsuit claims that Capricor Therapeutics failed to disclose material information about the drug's clinical trials, which ultimately led to a significant drop in the company's stock price.

Levi has a track record of success in securities litigation, having recovered millions of dollars for his clients in past cases. He is known for his tenacity and his willingness to take on complex and challenging cases. Levi's expertise in securities law and his commitment to protecting the rights of investors make him a valuable asset to the Levi &amp; Korsinsky team.

Overall, Joseph E. Levi and Levi &amp; Korsinsky, LLP are well-respected in the legal community for their work in representing investors in securities litigation. Levi's involvement in the Capricor Therapeutics lawsuit is a testament to his dedication to his clients and his commitment to ensuring that they receive the justice they deserve.</data>
    </edge>
    <edge id="e67" source="1" target="52">
      <data key="d3">8.0</data>
      <data key="d4">litigation challenging merger...</data>
      <data key="d6">Chen was involved in litigation challenging the merger of Occam Networks, Inc. and Calix, Inc.</data>
    </edge>
    <edge id="e68" source="1" target="53">
      <data key="d3">8.0</data>
      <data key="d4">litigation challenging merger...</data>
      <data key="d6">Howard-Anderson was involved in litigation challenging the merger of Occam Networks, Inc. and Calix, Inc.</data>
    </edge>
    <edge id="e69" source="3" target="54">
      <data key="d3">8.0</data>
      <data key="d4">litigation challenging acquisition...</data>
      <data key="d6">Weigard was involved in litigation challenging the acquisition of Health Grades, Inc. by Vestar Capital Partners, L.P.</data>
    </edge>
    <edge id="e70" source="3" target="55">
      <data key="d3">8.0</data>
      <data key="d4">litigation challenging acquisition...</data>
      <data key="d6">Hicks was involved in litigation challenging the acquisition of Health Grades, Inc. by Vestar Capital Partners, L.P.</data>
    </edge>
    <edge id="e71" source="5" target="56">
      <data key="d3">1.0</data>
      <data key="d4">CNX Gas Corp....</data>
      <data key="d6">Strine was involved in the CNX Gas Corp. shareholder litigation case</data>
    </edge>
    <edge id="e72" source="31" target="16">
      <data key="d3">18.0</data>
      <data key="d4">Managing Partner Co-Founder...</data>
      <data key="d6">Eduard Korsinsky is the Managing Partner and Co-Founder of Levi &amp; Korsinsky LLP, a national securities firm that has recovered billions of dollars for investors.</data>
    </edge>
    <edge id="e73" source="16" target="32">
      <data key="d3">8.0</data>
      <data key="d4">LLP achieved million...</data>
      <data key="d6">Levi &amp; Korsinsky LLP achieved a $79 million recovery for investors of E-Trade Financial Corporation.</data>
    </edge>
    <edge id="e74" source="16" target="33">
      <data key="d3">8.0</data>
      <data key="d4">LLP achieved payment...</data>
      <data key="d6">Levi &amp; Korsinsky LLP achieved a payment ladder indemnifying investors of Google, Inc. up to $8 billion in losses on a ground-breaking corporate governance case.</data>
    </edge>
    <edge id="e75" source="16" target="34">
      <data key="d3">8.0</data>
      <data key="d4">LLP serves lead...</data>
      <data key="d6">Levi &amp; Korsinsky LLP serves as lead counsel in a securities matter involving Tesla.</data>
    </edge>
    <edge id="e76" source="16" target="35">
      <data key="d3">8.0</data>
      <data key="d4">LLP serves lead...</data>
      <data key="d6">Levi &amp; Korsinsky LLP serves as lead counsel in a securities matter involving US Steel.</data>
    </edge>
    <edge id="e77" source="16" target="36">
      <data key="d3">1.0</data>
      <data key="d4">LLP serves lead...</data>
      <data key="d6">Levi &amp; Korsinsky LLP serves as lead counsel in a securities matter involving Kraft Heinz.</data>
    </edge>
    <edge id="e78" source="57" target="0">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented QuantumScape...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented QuantumScape Corporation in a $47.5 million settlement</data>
    </edge>
    <edge id="e79" source="58" target="0">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented Loma...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented Loma Negra Industrial Argentina Sociedad Argentina in a $24.6 million settlement</data>
    </edge>
    <edge id="e80" source="59" target="0">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented Corcept...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented Corcept Therapeutics Incorporated in a $14 million settlement</data>
    </edge>
    <edge id="e81" source="60" target="0">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented Babcock...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented Babcock &amp; Wilcox Enterprises, Inc. in a $9.5 million settlement</data>
    </edge>
    <edge id="e82" source="61" target="0">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented Steel...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented U.S. Steel in a $40 million settlement</data>
    </edge>
    <edge id="e83" source="62" target="0">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented Aqua...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented Aqua Metals, Inc. in a $7 million settlement</data>
    </edge>
    <edge id="e84" source="63" target="0">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented WideOpenWest,...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented WideOpenWest, Inc. in a $7.025 million settlement</data>
    </edge>
    <edge id="e85" source="64" target="0">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented Helios...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented Helios and Matheson Analytics Inc. in an $8.25 million settlement</data>
    </edge>
    <edge id="e86" source="65" target="0">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented Illumina,...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented Illumina, Inc. in a $13.85 million settlement</data>
    </edge>
    <edge id="e87" source="66" target="0">
      <data key="d3">9.0</data>
      <data key="d4">LLP represented Avon...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP represented Avon Products Inc. in a $14.5 million settlement</data>
    </edge>
    <edge id="e88" source="67" target="0">
      <data key="d3">9.0</data>
      <data key="d4">praised handling...</data>
      <data key="d6">Ronald B. Rubin praised the handling of a case by Levi &amp; Korsinsky, LLP</data>
    </edge>
    <edge id="e89" source="68" target="0">
      <data key="d3">9.0</data>
      <data key="d4">praised conduct...</data>
      <data key="d6">Timothy S. Driscoll praised the conduct of the legal profession, including Levi &amp; Korsinsky, LLP</data>
    </edge>
    <edge id="e90" source="69" target="0">
      <data key="d3">9.0</data>
      <data key="d4">found Levi Korsinsky,...</data>
      <data key="d6">Andrew L. Carter, Jr. found Levi &amp; Korsinsky, LLP to be well-qualified to serve as Lead Counsel</data>
    </edge>
    <edge id="e91" source="70" target="0">
      <data key="d3">9.0</data>
      <data key="d4">Levi Korsinsky, LLP's...</data>
      <data key="d6">Analisa Torres noted Levi &amp; Korsinsky, LLP's "extensive experience" in securities litigation</data>
    </edge>
    <edge id="e92" source="71" target="0">
      <data key="d3">1.0</data>
      <data key="d4">found class counsel,...</data>
      <data key="d6">Barry Ted Moskowitz found the class counsel, including Levi &amp; Korsinsky, LLP, to be skilled and adequate to represent the settlement class</data>
    </edge>
    <edge id="e93" source="72" target="73">
      <data key="d3">9.0</data>
      <data key="d4">trial drug fasedienol...</data>
      <data key="d6">Vistagen's Phase 3 trial for its drug fasedienol did not meet the primary endpoint for treating social anxiety disorder</data>
    </edge>
    <edge id="e94" source="72" target="74">
      <data key="d3">8.0</data>
      <data key="d4">class action lawsuit...</data>
      <data key="d6">Deadline for filing class action lawsuit against Vistagen Therapeutics, Inc. is March 16 2026</data>
    </edge>
    <edge id="e95" source="75" target="77">
      <data key="d3">5.0</data>
      <data key="d4">risk trading...</data>
      <data key="d6">SDM Securities was at risk of a trading suspension by the SEC</data>
    </edge>
    <edge id="e96" source="76" target="77">
      <data key="d3">5.0</data>
      <data key="d4">risk trading...</data>
      <data key="d6">SDM Securities was at risk of a trading suspension by NASDAQ</data>
    </edge>
    <edge id="e97" source="78" target="0">
      <data key="d3">1.0</data>
      <data key="d4">serving lead counsel...</data>
      <data key="d6">Levi &amp; Korsinsky is serving as lead counsel in the Tronox Holdings PLC lawsuit</data>
    </edge>
    <edge id="e98" source="0" target="81">
      <data key="d3">21.0</data>
      <data key="d4">LLP, law firm,...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP, a law firm, has commenced an investigation of Alector, Inc., a biotechnology company, concerning possible violations of federal securities laws. The investigation is focused on determining whether Alector, Inc. engaged in any fraudulent activities.

According to the available information, Levi &amp; Korsinsky, LLP is looking into the possibility of Alector, Inc. committing fraud. The law firm is conducting this investigation to determine if there are any grounds for legal action against the biotechnology company.

Alector, Inc. is a clinical-stage biotechnology company that is focused on developing therapies for neurodegenerative diseases. The company's lead product candidate, AL001, is currently in clinical trials for the treatment of frontotemporal dementia.

The investigation by Levi &amp; Korsinsky, LLP is likely related to the company's financial disclosures and the performance of its stock. Investors may have raised concerns about the company's financial reporting or the progress of its clinical trials, leading to the law firm's investigation.

It is important to note that the investigation is still ongoing, and no definitive conclusions have been reached regarding any potential wrongdoing by Alector, Inc. The law firm is conducting a thorough review of the available information to determine if there are any grounds for legal action.

In summary, Levi &amp; Korsinsky, LLP has initiated an investigation into Alector, Inc. regarding possible violations of federal securities laws. The investigation is focused on determining whether the biotechnology company has engaged in any fraudulent activities. The outcome of this investigation will be crucial in understanding the company's financial and operational practices and their impact on investors.</data>
    </edge>
    <edge id="e99" source="79" target="81">
      <data key="d3">16.0</data>
      <data key="d4">developing latozinemab (AL001)...</data>
      <data key="d6">Alector, Inc. is developing latozinemab (AL001) as a treatment for frontotemporal dementia due to a progranulin gene mutation (FTD-GRN)</data>
    </edge>
    <edge id="e100" source="79" target="80">
      <data key="d3">9.0</data>
      <data key="d4">being evaluated treatment...</data>
      <data key="d6">Latozinemab (AL001) was being evaluated as a treatment for frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) in the Phase 2 INFRONT-3 clinical trial</data>
    </edge>
    <edge id="e101" source="81" target="76">
      <data key="d3">1.0</data>
      <data key="d4">listed NASDAQ stock...</data>
      <data key="d6">Alector, Inc. is listed on the NASDAQ stock exchange</data>
    </edge>
    <edge id="e102" source="72" target="12">
      <data key="d3">18.0</data>
      <data key="d4">filed securities class...</data>
      <data key="d6">Levi &amp; Korsinsky filed a securities class action lawsuit against Vistagen Therapeutics on behalf of its shareholders</data>
    </edge>
    <edge id="e103" source="72" target="82">
      <data key="d3">10.0</data>
      <data key="d4">trial clinical...</data>
      <data key="d6">The PALISADE-3 Phase 3 trial was a clinical study of Vistagen's drug fasedienol</data>
    </edge>
    <edge id="e104" source="72" target="76">
      <data key="d3">9.0</data>
      <data key="d4">biopharmaceutical company that...</data>
      <data key="d6">VISTAGEN THERAPEUTICS, INC. is a biopharmaceutical company that is publicly traded on the NASDAQ stock exchange. The company is focused on developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need.

Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California. The company's pipeline includes several drug candidates in various stages of development, including PH94B, PH10, and AV-101. These drug candidates are being evaluated for the treatment of social anxiety disorder, major depressive disorder, and neuropathic pain, respectively.

PH94B is Vistagen's lead product candidate and is currently in late-stage clinical trials for the treatment of social anxiety disorder. The drug is a novel, rapid-acting, non-sedating, and non-addictive investigational pheripheral neuropeptide agonist. PH10 is another investigational drug candidate that is being developed for the treatment of major depressive disorder. AV-101 is Vistagen's third drug candidate, which is being evaluated for the treatment of neuropathic pain.

Vistagen Therapeutics is publicly traded on the NASDAQ stock exchange under the ticker symbol "VTGN". The company's shares are listed on the NASDAQ, which is one of the world's largest stock exchanges and is known for its focus on technology and innovation. By being listed on the NASDAQ, Vistagen Therapeutics has access to a larger pool of investors and increased visibility in the biopharmaceutical industry.

Overall, Vistagen Therapeutics is a biopharmaceutical company that is focused on developing new generation medicines for central nervous system diseases and disorders. The company is publicly traded on the NASDAQ stock exchange, which provides it with access to capital and increased visibility in the industry.</data>
    </edge>
    <edge id="e105" source="6" target="12">
      <data key="d3">16.0</data>
      <data key="d4">attorney Levi...</data>
      <data key="d6">Joseph E. Levi is an attorney at Levi &amp; Korsinsky representing Vistagen Therapeutics shareholders</data>
    </edge>
    <edge id="e106" source="12" target="83">
      <data key="d3">1.0</data>
      <data key="d4">used Globe Newswire...</data>
      <data key="d6">Levi &amp; Korsinsky used Globe Newswire to announce the filing of the securities class action lawsuit</data>
    </edge>
    <edge id="e107" source="59" target="12">
      <data key="d3">17.0</data>
      <data key="d4">pharmaceutical company that...</data>
      <data key="d6">Corcept Therapeutics Incorporated is a pharmaceutical company that specializes in the development and commercialization of drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders. The company's lead product, Korlym, is approved for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome.

Recently, Levi &amp; Korsinsky, a law firm, has commenced an investigation into potential securities fraud by Corcept Therapeutics. The investigation is focused on determining whether Corcept Therapeutics and its officers or directors have engaged in securities fraud or other unlawful business practices.

According to the information provided, Levi &amp; Korsinsky is investigating possible securities fraud by Corcept Therapeutics Incorporated. The law firm is looking into the company's business practices and financial reporting to determine if there have been any violations of federal securities laws.

The investigation by Levi &amp; Korsinsky is still ongoing, and the firm has not yet made any specific allegations against Corcept Therapeutics or its management. However, the fact that the law firm has initiated an investigation suggests that there may be concerns about the company's financial reporting or other business practices.

It is important to note that the investigation by Levi &amp; Korsinsky is not a finding of wrongdoing by Corcept Therapeutics. The company has not been charged with any crimes or civil violations, and the investigation is still in the preliminary stages.

Corcept Therapeutics has not yet commented publicly on the investigation by Levi &amp; Korsinsky. The company may choose to cooperate with the investigation or to defend itself against any potential allegations.

In summary, Corcept Therapeutics Incorporated is a pharmaceutical company that is currently under investigation by the law firm Levi &amp; Korsinsky for potential securities fraud. The investigation is ongoing, and no specific allegations have been made against the company or its management. Corcept Therapeutics has not yet responded publicly to the investigation.</data>
    </edge>
    <edge id="e108" source="84" target="59">
      <data key="d3">16.0</data>
      <data key="d4">approval Corcept's new...</data>
      <data key="d6">The FDA denied approval of Corcept's new drug application for relacorilant, citing the need for additional evidence of effectiveness</data>
    </edge>
    <edge id="e109" source="85" target="59">
      <data key="d3">14.0</data>
      <data key="d4">results Corcept's previous...</data>
      <data key="d6">The FDA acknowledged the results of Corcept's previous GRACE drug trial</data>
    </edge>
    <edge id="e110" source="86" target="59">
      <data key="d3">14.0</data>
      <data key="d4">results Corcept's previous...</data>
      <data key="d6">The FDA acknowledged the results of Corcept's previous GRADIENT drug trial</data>
    </edge>
    <edge id="e111" source="87" target="59">
      <data key="d3">10.0</data>
      <data key="d4">relacorilant treatment...</data>
      <data key="d6">Corcept Therapeutics developed relacorilant as a treatment for hypertension secondary to hypercortisolism</data>
    </edge>
    <edge id="e112" source="59" target="76">
      <data key="d3">1.0</data>
      <data key="d4">publicly traded company...</data>
      <data key="d6">Corcept Therapeutics is a publicly traded company listed on the NASDAQ stock exchange</data>
    </edge>
    <edge id="e113" source="59" target="88">
      <data key="d3">9.0</data>
      <data key="d4">marketed Korlym (mifepristone)...</data>
      <data key="d6">Corcept Therapeutics has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushing's syndrome.</data>
    </edge>
    <edge id="e114" source="59" target="87">
      <data key="d3">8.0</data>
      <data key="d4">selective cortisol modulator...</data>
      <data key="d6">Relacorilant is a selective cortisol modulator in Corcept Therapeutics' portfolio of drug candidates.</data>
    </edge>
    <edge id="e115" source="59" target="90">
      <data key="d3">8.0</data>
      <data key="d4">selective cortisol modulator...</data>
      <data key="d6">Exicorilant is a selective cortisol modulator in Corcept Therapeutics' portfolio of drug candidates.</data>
    </edge>
    <edge id="e116" source="59" target="91">
      <data key="d3">8.0</data>
      <data key="d4">selective cortisol modulator...</data>
      <data key="d6">Dazucorilant is a selective cortisol modulator in Corcept Therapeutics' portfolio of drug candidates.</data>
    </edge>
    <edge id="e117" source="59" target="92">
      <data key="d3">8.0</data>
      <data key="d4">selective cortisol modulator...</data>
      <data key="d6">Miricorilant is a selective cortisol modulator in Corcept Therapeutics' portfolio of drug candidates.</data>
    </edge>
    <edge id="e118" source="88" target="89">
      <data key="d3">1.0</data>
      <data key="d4">used treat patients...</data>
      <data key="d6">Korlym (mifepristone) is used to treat patients suffering from Cushing's syndrome.</data>
    </edge>
    <edge id="e119" source="12" target="59">
      <data key="d3">9.0</data>
      <data key="d4">investigating possible securities...</data>
      <data key="d6">Levi &amp; Korsinsky is investigating possible securities fraud by Corcept Therapeutics Incorporated</data>
    </edge>
    <edge id="e120" source="59" target="93">
      <data key="d3">7.0</data>
      <data key="d4">quotes Corcept Therapeutics...</data>
      <data key="d6">FactSet provides stock quotes for Corcept Therapeutics Incorporated</data>
    </edge>
    <edge id="e121" source="59" target="94">
      <data key="d3">7.0</data>
      <data key="d4">quotes Corcept Therapeutics...</data>
      <data key="d6">Morningstar provides stock quotes for Corcept Therapeutics Incorporated</data>
    </edge>
    <edge id="e122" source="59" target="95">
      <data key="d3">1.0</data>
      <data key="d4">provides stock quotes...</data>
      <data key="d6">S&amp;P Capital IQ provides stock quotes for Corcept Therapeutics Incorporated</data>
    </edge>
    <edge id="e123" source="0" target="96">
      <data key="d3">10.0</data>
      <data key="d4">comprehensive summary data...</data>
      <data key="d6">Here is a comprehensive summary of the data provided:

Levi &amp; Korsinsky, LLP, a law firm, has filed a class action lawsuit against E.L.F. Beauty, Inc., a cosmetics company, for alleged securities law violations and securities fraud. 

According to the lawsuit, Levi &amp; Korsinsky is representing investors who purchased E.L.F. Beauty securities during a specific time period. The lawsuit alleges that E.L.F. Beauty made false and/or misleading statements and/or failed to disclose information pertaining to its business, operations, and prospects. This allegedly resulted in the company's stock trading at artificially inflated prices, before the true details came to light and the stock price declined, causing losses for investors.

The specific details of the alleged securities law violations and fraud are not provided in the information given. However, the core allegation is that E.L.F. Beauty misled investors about aspects of its business, leading to investor losses when the truth was revealed. 

Levi &amp; Korsinsky, as the law firm representing the class of investors, is seeking to recover damages on behalf of those who purchased E.L.F. Beauty securities during the relevant time period and were allegedly harmed by the company's actions. The lawsuit aims to hold E.L.F. Beauty accountable for the claimed securities law violations and securities fraud.

In summary, Levi &amp; Korsinsky, LLP has filed a class action lawsuit against E.L.F. Beauty, Inc. for alleged securities law violations and securities fraud, which the law firm claims resulted in investor losses. The specific details of the alleged misconduct are not provided, but the overall allegation is that E.L.F. Beauty made false or misleading statements that artificially inflated its stock price before the truth came to light.</data>
    </edge>
    <edge id="e124" source="96" target="97">
      <data key="d3">7.0</data>
      <data key="d4">listed New...</data>
      <data key="d6">e.l.f. Beauty, Inc. is listed on the New York Stock Exchange</data>
    </edge>
    <edge id="e125" source="0" target="98">
      <data key="d3">7.0</data>
      <data key="d4">investigated Corcept possible...</data>
      <data key="d6">Levi &amp; Korsinsky investigated Corcept for possible securities fraud violations</data>
    </edge>
    <edge id="e126" source="0" target="10">
      <data key="d3">17.0</data>
      <data key="d4">LLP, law firm,...</data>
      <data key="d6">Levi &amp; Korsinsky, LLP, a law firm, has filed a securities fraud class action lawsuit against Capricor Therapeutics, Inc., a biopharmaceutical company. The lawsuit alleges that Capricor Therapeutics engaged in securities fraud, which adversely affected investors.

According to the lawsuit filed by Levi &amp; Korsinsky, the firm is representing a class of investors who were affected by the alleged securities fraud committed by Capricor Therapeutics. The lawsuit claims that the company made false and misleading statements or failed to disclose material information about its business and operations, which resulted in investors suffering losses.

Capricor Therapeutics is a clinical-stage biotechnology company that focuses on the development of cell and exosome-based therapies for the treatment of various diseases. The company's lead product candidate is CAP-1002, a cell therapy for the treatment of Duchenne muscular dystrophy.

The lawsuit against Capricor Therapeutics alleges that the company made false or misleading statements regarding the development and potential of its lead product candidate, CAP-1002. The lawsuit claims that the company failed to disclose material information about the product's clinical trials and the likelihood of its approval by regulatory authorities.

Levi &amp; Korsinsky, the law firm that filed the lawsuit, is a national firm that specializes in class action lawsuits and securities fraud cases. The firm has a track record of representing investors in cases against publicly traded companies that have allegedly engaged in securities fraud or other misconduct.

The lawsuit against Capricor Therapeutics is seeking to recover damages on behalf of the affected investors. The class action lawsuit is an attempt to hold the company accountable for its alleged actions and to provide compensation to the investors who were harmed by the company's alleged misconduct.

It is important to note that the allegations made in the lawsuit have not been proven in court, and the case is still ongoing. The outcome of the lawsuit will depend on the evidence presented and the final decision of the court.</data>
    </edge>
    <edge id="e127" source="0" target="72">
      <data key="d3">26.0</data>
      <data key="d4">comprehensive summary data...</data>
      <data key="d6">Here is a comprehensive summary of the data provided:

Levi &amp; Korsinsky, LLP, a law firm, has filed a securities fraud class action lawsuit against Vistagen Therapeutics, Inc., a biopharmaceutical company. The lawsuit is related to Vistagen's PALISADE-3 clinical trial.

According to the lawsuit filed by Levi &amp; Korsinsky, Vistagen Therapeutics made false and/or misleading statements and/or failed to disclose information pertaining to the PALISADE-3 trial. The PALISADE-3 trial was a Phase 3 clinical study evaluating Vistagen's drug candidate, PH94B, as a potential treatment for social anxiety disorder.

The lawsuit alleges that Vistagen misled investors about the likelihood of the PALISADE-3 trial's success and the drug's potential for regulatory approval. Specifically, the lawsuit claims that Vistagen failed to disclose issues with the trial design and execution, which ultimately led to the trial's failure to meet its primary endpoint.

The securities fraud class action lawsuit seeks to recover damages on behalf of investors who purchased Vistagen Therapeutics' securities during the class period. The class period is not specified in the provided information.

Levi &amp; Korsinsky, LLP is a law firm that specializes in securities litigation and has filed the class action lawsuit against Vistagen Therapeutics. The firm is seeking to represent all investors who were affected by Vistagen's alleged misconduct related to the PALISADE-3 trial.

In summary, Levi &amp; Korsinsky, LLP has filed a securities fraud class action lawsuit against Vistagen Therapeutics, Inc. The lawsuit alleges that Vistagen made false and/or misleading statements and/or failed to disclose material information related to the PALISADE-3 clinical trial of its drug candidate, PH94B, for the treatment of social anxiety disorder. The lawsuit seeks to recover damages on behalf of investors who were affected by Vistagen's alleged misconduct.</data>
    </edge>
    <edge id="e128" source="82" target="72">
      <data key="d3">18.0</data>
      <data key="d4">conducting PALISADE-3 Phase...</data>
      <data key="d6">Vistagen Therapeutics, Inc. was conducting the PALISADE-3 Phase 3 clinical trial study of fasedienol for the acute treatment of social anxiety disorder</data>
    </edge>
    <edge id="e129" source="99" target="72">
      <data key="d3">10.0</data>
      <data key="d4">investigational pherine candidate...</data>
      <data key="d6">Fasedienol is an investigational pherine candidate developed by Vistagen Therapeutics, Inc. for the acute treatment of social anxiety disorder</data>
    </edge>
    <edge id="e130" source="100" target="10">
      <data key="d3">22.0</data>
      <data key="d4">Capricor Therapeutics, Inc....</data>
      <data key="d6">The HOPE-2 Trial and Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of innovative therapies for the treatment of cardiovascular and other serious medical conditions. The company conducted the Phase 2 HOPE-2 clinical trial to evaluate the safety and efficacy of deramiocel, an investigational therapy.

The HOPE-2 trial was a Phase 2 clinical trial conducted by Capricor Therapeutics to evaluate the safety and efficacy of deramiocel. Deramiocel is a cell therapy product derived from allogeneic cardiosphere-derived cells (CDCs), which are isolated from the patient's own heart tissue. The trial was designed to assess the potential of deramiocel to improve cardiac function and clinical outcomes in patients with Duchenne muscular dystrophy (DMD)-associated cardiomyopathy.

DMD is a rare and devastating genetic disorder that primarily affects boys, causing progressive muscle weakness and degeneration. Cardiomyopathy, or weakening of the heart muscle, is a common and life-threatening complication of DMD, often leading to heart failure and premature death. The HOPE-2 trial aimed to evaluate whether deramiocel, with its potential to regenerate and repair damaged heart tissue, could improve cardiac function and clinical outcomes in these patients.

The trial enrolled patients with DMD-associated cardiomyopathy and randomized them to receive either deramiocel or a placebo. The primary endpoint of the study was the change in left ventricular ejection fraction (LVEF), a measure of the heart's pumping ability, at 12 months. Secondary endpoints included other measures of cardiac function, as well as assessments of physical function and quality of life.

The results of the HOPE-2 trial are eagerly awaited, as they will provide important insights into the potential of deramiocel as a novel therapeutic approach for the management of DMD-associated cardiomyopathy. If the trial demonstrates the safety and efficacy of deramiocel, it could represent a significant advancement in the treatment of this devastating condition, offering hope to patients and their families.

In summary, the HOPE-2 Trial, conducted by Capricor Therapeutics, Inc., is a Phase 2 clinical study evaluating the safety and efficacy of deramiocel, a cell therapy product, in patients with Duchenne muscular dystrophy-associated cardiomyopathy. The trial aims to assess the potential of deramiocel to improve cardiac function and clinical outcomes in this patient population, with the goal of providing a new therapeutic option for this devastating condition.</data>
    </edge>
    <edge id="e131" source="10" target="84">
      <data key="d3">16.0</data>
      <data key="d4">Capricor's Biologics License...</data>
      <data key="d6">The FDA denied Capricor's Biologics License Application (BLA) for deramiocel, citing a lack of substantial evidence of effectiveness and the need for additional clinical data</data>
    </edge>
    <edge id="e132" source="10" target="101">
      <data key="d3">1.0</data>
      <data key="d4">Biologics License Application...</data>
      <data key="d6">Capricor Therapeutics submitted a Biologics License Application (BLA) for deramiocel, which was denied by the FDA</data>
    </edge>
    <edge id="e133" source="34" target="102">
      <data key="d3">1.0</data>
      <data key="d4">stock ticker symbol...</data>
      <data key="d6">TSLA is the stock ticker symbol for the Tesla organization.</data>
    </edge>
    <edge id="e134" source="11" target="10">
      <data key="d3">8.0</data>
      <data key="d4">Biologics License Application...</data>
      <data key="d6">Capricor submitted a Biologics License Application to the FDA for approval of deramiocel</data>
    </edge>
    <edge id="e135" source="11" target="101">
      <data key="d3">9.0</data>
      <data key="d4">approves Biologics License...</data>
      <data key="d6">The FDA reviews and approves Biologics License Applications for biological products like cell therapies</data>
    </edge>
    <edge id="e136" source="13" target="10">
      <data key="d3">9.0</data>
      <data key="d4">developing deramiocel lead...</data>
      <data key="d6">Capricor Therapeutics is developing deramiocel as its lead cell therapy candidate drug</data>
    </edge>
    <edge id="e137" source="103" target="10">
      <data key="d3">1.0</data>
      <data key="d4">Complete Response Letter...</data>
      <data key="d6">The FDA issued a Complete Response Letter to Capricor denying the BLA for deramiocel</data>
    </edge>
    <edge id="e138" source="10" target="0">
      <data key="d3">9.0</data>
      <data key="d4">filing securities fraud...</data>
      <data key="d6">Levi &amp; Korsinsky is filing a securities fraud class action lawsuit against Capricor Therapeutics on behalf of investors</data>
    </edge>
    <edge id="e139" source="15" target="0">
      <data key="d3">1.0</data>
      <data key="d4">attorney Levi...</data>
      <data key="d6">Ed Korsinsky is an attorney at Levi &amp; Korsinsky representing investors in the Capricor Therapeutics lawsuit</data>
    </edge>
    <edge id="e140" source="12" target="104">
      <data key="d3">2.0</data>
      <data key="d4">filed securities class...</data>
      <data key="d6">Levi &amp; Korsinsky has filed a securities class action lawsuit on behalf of Vistagen</data>
    </edge>
  </graph>
</graphml>